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Abstract
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease resulting from deficiency of the
enzyme α-L-iduronidase (IDUA). Accumulation of the IDUA substrates heparan and dermatan sulfate
causes widespread organ pathology. While many of the somatic manifestations of MPS I can be treated
with intravenous enzyme replacement, the devastating CNS sequelae—cognitive impairment, spinal cord
compression, and hydrocephalus—do not respond to treatment. Partial preservation of cognitive function
is possible with early hematopoietic stem cell transplantation, although transplant is associated with
substantial morbidity and mortality. Gene transfer using adeno-associated virus (AAV) vectors offers a
potential alternative approach to deliver the IDUA enzyme to the CNS. Introducing a functional IDUA gene
to a subset of quiescent cells could provide a permanent source of secreted enzyme beyond the bloodbrain barrier. However, preclinical studies evaluating direct injection of AAV vectors into the brain have
shown that transduction is limited to small regions surrounding the injection site, and that injection can
be associated with a localized inflammatory response and immune-mediated killing of transduced cells.
In order to overcome these limitations, we evaluated delivery of an AAV serotype 9 vector into the
cerebrospinal fluid as a less invasive method to achieve widespread brain transduction. Studies in
nonhuman primates demonstrated that intrathecal AAV9 delivery results in transduction of cells
throughout the brain and spinal cord without eliciting destructive immune responses to the transgene
product. Intrathecal injection of AAV9 vectors expressing IDUA in canine and feline models of MPS I
replicated the widespread transduction observed in primate studies, and demonstrated resolution of
storage lesions throughout the CNS. Antibodies against the enzyme were detected in the CSF of some
animals, which coincided with lower CSF IDUA activity and less efficient correction of storage lesions. We
found that immunological tolerance could be induced to IDUA by exposing newborn MPS I dogs to the
enzyme, which enhanced the efficacy of subsequent gene transfer. These results were replicated in
rhesus macaques, supporting the potential to translate neonatal tolerance induction to clinical
applications. Intrathecal AAV delivery offers the potential for widespread gene transfer in the CNS with a
single minimally invasive vector injection, which could prove transformative for the field of gene therapy
for inherited neurological disorders.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
James M. Wilson

Keywords
gene therapy, mucopolysaccharidosis

Subject Categories
Genetics | Medicine and Health Sciences | Molecular Biology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1763

INTRATHECAL ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR
MUCOPOLYSACCHARIDOSIS TYPE I

Christian Hinderer
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2015

Supervisor of Dissertation
_______________________
James M Wilson, MD PhD
Professor, Pathology and Laboratory Medicine

Graduate Group Chairperson
_______________________
Daniel S Kessler, PhD
Associate Professor, Cell and Developmental Biology
Dissertation Committee:
Philip R Johnson, MD, Professor of Pediatrics
Jean Bennett, MD PhD, Professor of Ophthalmology
Jean Boyer, PhD, Research Associate Professor of Pathology and Laboratory Medicine
Virginia Lee, PhD, Professor of Pathology and Laboratory Medicine

INTRATHECAL ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR
MUCOPOLYSACCHARIDOSIS TYPE I
COPYRIGHT
2015
Christian Hinderer

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 3.0
License

To view a copy of this license, visit
http://creativecommons.org/licenses/by-ny-sa/2.0/

ABSTRACT
INTRATHECAL ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR
MUCOPOLYSACCHARIDOSIS TYPE I
Christian Hinderer
James M Wilson, MD PhD

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease resulting from
deficiency of the enzyme α-L-iduronidase (IDUA). Accumulation of the IDUA substrates
heparan and dermatan sulfate causes widespread organ pathology. While many of the
somatic manifestations of MPS I can be treated with intravenous enzyme replacement,
the devastating CNS sequelae—cognitive impairment, spinal cord compression, and
hydrocephalus—do not respond to treatment. Partial preservation of cognitive function
is possible with early hematopoietic stem cell transplantation, although transplant is
associated with substantial morbidity and mortality. Gene transfer using adenoassociated virus (AAV) vectors offers a potential alternative approach to deliver the
IDUA enzyme to the CNS. Introducing a functional IDUA gene to a subset of quiescent
cells could provide a permanent source of secreted enzyme beyond the blood-brain
barrier. However, preclinical studies evaluating direct injection of AAV vectors into the
brain have shown that transduction is limited to small regions surrounding the injection
site, and that injection can be associated with a localized inflammatory response and
immune-mediated killing of transduced cells. In order to overcome these limitations, we
evaluated delivery of an AAV serotype 9 vector into the cerebrospinal fluid as a less
invasive method to achieve widespread brain transduction. Studies in nonhuman
primates demonstrated that intrathecal AAV9 delivery results in transduction of cells
throughout the brain and spinal cord without eliciting destructive immune responses to
the transgene product. Intrathecal injection of AAV9 vectors expressing IDUA in canine
and feline models of MPS I replicated the widespread transduction observed in primate
studies, and demonstrated resolution of storage lesions throughout the CNS. Antibodies
against the enzyme were detected in the CSF of some animals, which coincided with
lower CSF IDUA activity and less efficient correction of storage lesions. We found that
immunological tolerance could be induced to IDUA by exposing newborn MPS I dogs to
the enzyme, which enhanced the efficacy of subsequent gene transfer. These results
were replicated in rhesus macaques, supporting the potential to translate neonatal
tolerance induction to clinical applications. Intrathecal AAV delivery offers the potential
for widespread gene transfer in the CNS with a single minimally invasive vector injection,
which could prove transformative for the field of gene therapy for inherited neurological
disorders.
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CHAPTER 1: Introduction
Mucopolysaccharidosis type I
Mucopolysaccharidosis type I (MPS I) is a rare genetic disease affecting
approximately 1 in 100,000 newborns worldwide (Moore et al. 2008). Children with MPS
I typically appear normal at birth, although umbilical hernias or spinal deformities are
sometimes present (Beck et al. 2014).

Often after one to two years of normal

development, patients rapidly develop a constellation of devastating disease
manifestations—chronic upper respiratory infections, joint pain and immobility, bone
deformities, coarsened facial features, hepatomegaly, carpal tunnel syndrome,
communicating hydrocephalus, spinal cord compression, hearing impairment, corneal
clouding, obstructive sleep apnea, and cardiac disease (Beck et al. 2014, Aldenboven,
Boelens, and de Koning 2008, Boelens et al. 2007, Souillet et al. 2003, Whitley et al.
1993). Most patients also begin to show signs of developmental delay by 2 years of
age, which progresses to profound intellectual impairment in early childhood. Without
treatment most patients do not survive beyond the first decade (Aldenboven, Boelens,
and de Koning 2008, Boelens et al. 2007, Fleming et al. 1998, Souillet et al. 2003, Staba
et al. 2004, Whitley et al. 1993).
MPS I is caused by mutations in the IDUA gene encoding the lysosomal enzyme
α-L-iduronidase (IDUA).

IDUA catalyzes the hydrolysis of iduronic acid linkages in

heparan and dermatan sulfate, two ubiquitous glycosaminoglycans (GAG). In the setting
of deficient IDUA activity, undegraded GAGs accumulate in nearly every tissue, leading
to diverse clinical manifestations.

GAG storage in the cornea causes characteristic

clouding and visual impairment, airway abnormalities caused by GAG infiltration
1

contribute to obstructive sleep apnea and chronic upper respiratory infections, and
storage lesions in the cardiac valves cause the valves to thicken and shorten, leading to
mitral and aortic regurgitation.

Both spinal cord compression and communicating

hydrocephalus have been linked to GAG storage in the meninges—the thickened dura
mater directly compresses the spinal cord, and leptomeningeal GAG storage is thought
to block perivascular channels and arachnoid granulations through which CSF is
resorbed, leading to increased CSF pressure (Dickson, Hanson, et al. 2010, Kakkis,
McEntee, et al. 2004, Munoz-Rojas et al. 2008, Kachur and Del Maestro 2000, Taccone
et al. 1993). The mechanism by which IDUA deficiency leads to cognitive dysfunction is
less clear; neurons exhibit GAG storage, but this does not appear to correlate with
disease onset or severity. Neurons do, however, exhibit marked abnormalities. Ectopic
neurite growth, axonal spheroids, and storage of gangliosides are pronounced in cortical
neurons, and these features correlate with cognitive phenotype in MPS I as well as in
related lysosomal storage disorders (Constantopoulos, Iqbal, and Dekaban 1980, Shull
et al. 1984, Walkley and Vanier 2009). It is not clear how the primary biochemical defect
leads to these downstream consequences in the brain.
MPS I patients present across a spectrum of severity, ranging from the most
common and severe presentation of early somatic involvement and rapid cognitive
decline, to onset after the first decade of life with attenuated somatic disease and normal
intelligence (Beck et al. 2014). The disease phenotype is related to residual enzyme
activity—patients with the attenuated form of MPS I typically have missense mutations,
whereas patients with severe disease have nonsense mutations, deletions or insertions
(Terlato and Cox 2003). In the US the most frequent mutations are W402X and Q70X,
both of which cause the severe form of the disease in homozygotes or compound
2

heterozygotes. The disease causing mutations that result in an attenuated phenotype
produce less than 1% of normal IDUA activity, demonstrating that very low levels of
enzyme can modify the course of the disease (Terlato and Cox 2003).
The first therapy developed for MPS I was hematopoietic stem cell
transplantation (HSCT). HSCT can impact systemic storage pathology through the
principle of cross correction: upon successful engraftment of HSCs, donor derived cells
secrete small amounts of IDUA, which is taken up by host cells from the systemic
circulation through receptor-mediated binding of terminal mannose-6 phosphate
residues present on glycosylated IDUA (Dahms, Lobel, and Kornfeld 1989, Sando and
Neufeld 1977, Aldenboven, Boelens, and de Koning 2008). Uptake of IDUA through this
pathway results in trafficking to the lysosome, where the enzyme catalyzes the
degradation of stored polysaccharides. HSCT has demonstrated improvements in
survival, growth, cardiac and respiratory function, mobility, and intellect. The effect of
HSCT on the CNS is attributed to migration of bone marrow derived precursors across
the blood-brain barrier, where they differentiate into microglia and serve as a source of
secreted IDUA in the brain (Aldenboven, Boelens, and de Koning 2008).
Despite the impact of HSCT on the clinical course of MPS I, there are important
limitations of the procedure. HSCT for MPS I is associated with substantial morbidity and
up to 20% mortality (Aldenboven, Boelens, and de Koning 2008). Accordingly, the
procedure is now reserved only for patients with severe disease. HSCT is also generally
only performed in patients identified before two years of age, as the risk-benefit ratio is
thought to be more favorable in younger patients who are more likely to derive greater
cognitive benefit (de Ru et al. 2011). A second critical limitation of HSCT is the
incomplete treatment of CNS symptoms.
3

Among successfully engrafted patients,

cognitive decline continues for up to a year after transplant before stabilizing, leaving
permanent developmental deficits (Fleming et al. 1998, Staba et al. 2004). This delayed
effect of HSCT is believed to be due to the time required for bone marrow-derived
microglia to migrate into the CNS. Studies in animal models suggest that only 30% of
microglial engraftment occurs by one year after transplant, with most of these engrafted
cells occupying perivascular spaces rather than the brain parenchyma (Kennedy and
Abkowitz 1997). There is therefore little improvement in neuronal storage lesions within
the first year after transplantation (Ellinwood et al. 2007).
More recently, a recombinant form of human IDUA has been approved for the
treatment of MPS I. Given as a weekly intravenous infusion, enzyme replacement
therapy (ERT) has demonstrated many of the same benefits as HSCT, including
improvement in hepatomegaly, growth, mobility and respiratory function (de Ru et al.
2011, Sifuentes et al. 2007, Wraith et al. 2007, Wraith et al. 2004). However, as the
enzyme cannot cross the blood-brain barrier, ERT does not treat the CNS
manifestations of MPS I.

Several studies have investigated the direct delivery of

recombinant IDUA to the CNS by intrathecal (IT) injection (Dickson, Naylor, Mlikotic,
Victoroff, Chen, Passage, and Le 2008, Dickson, Naylor, Mlikotic, Victoroff, Chen,
Passage, Le, et al. 2008, Munoz-Rojas et al. 2008, Vera et al. 2013). Monthly IT
infusions of IDUA demonstrated minimal adverse effects, and have shown evidence for
improvement in spinal cord compression. However, IT ERT has limited potential for the
treatment of CNS disease in MPS I due to the need for repeated access to the
cerebrospinal fluid (CSF) for the life of the patient. Further, the efficacy of this approach
is likely limited by the extremely short half-life of the enzyme in the CSF and the long
intervals between injections (Vite et al. 2011).
4

Adeno-associated virus mediated gene therapy for MPS I
The limitations of HSCT and ERT leave a significant unmet need for a method to
safely achieve long term IDUA reconstitution in the CNS. Delivery of the gene encoding
the enzyme to cells within the CNS could provide a permanent source of secreted IDUA
beyond the blood-brain barrier, allowing for long term cross-correction of cells
throughout the CNS. This strategy could also provide rapid IDUA delivery to the brain,
potentially preventing the progression of developmental deficits that otherwise occurs in
Hurler patients during the slow process of donor cell migration into the CNS following
HSCT.
Adeno-associated virus (AAV) vectors have demonstrated the potential for safe,
long term transgene expression in vivo. The wild type AAV from which these vectors are
derived is a small non-enveloped parvovirus that is ubiquitous in humans and other
species (Samulski and Muzyczka 2014).

AAV is nonpathogenic and has limited

replicative capacity in the absence of a helper virus. AAV is composed of a 20 nm
icosahedral capsid containing a 4.7 kb single-stranded DNA genome. The genome
contains three protein coding genes—Rep, Cap, and AAP—flanked by short doublestranded inverted terminal repeats. The Rep gene encodes four proteins required for
the replication and packaging of the genome. Cap encodes three proteins—VP1, VP2
and VP3—that form the viral capsid. AAP (assembly activator protein) is expressed
from an alternate reading frame overlapping Cap, and appears to have a role in capsid
assembly (Sonntag, Schmidt, and Kleinschmidt 2010). Only the inverted repeats are
essential for DNA packaging in AAV; the other essential proteins can be provided in
trans (Samulski, Chang, and Shenk 1989, 1987). Completely replacing the viral coding
sequences of AAV has yielded vectors capable of in vivo gene transfer. Upon entering a
5

host cell, the vector genome persists as an episome, allowing for stable expression for at
least ten years in quiescent tissues (Buchlis et al. 2012). However, early clinical trials
utilizing AAV vectors showed limited gene transfer and poor efficacy. Over the past
decade, a second generation of AAV vectors discovered as latent viruses in human and
macaque tissues has demonstrated vastly improved gene transfer efficiency over that
achieved with the original vectors based on AAV serotype 2 (AAV2) (Gao et al. 2004,
Gao et al. 2002, Xiao et al. 1999). Using these new vectors, clinical trials of gene
transfer to both liver and muscle have demonstrated efficacy in diseases such as
hemophilia B and lipoprotein lipase deficiency, the latter leading to the first approved
gene therapy product in Europe (Nathwani et al. 2011, Bryant et al. 2013).
AAV vectors have been tested extensively for gene transfer to the brain. One of
the most heavily pursued CNS targets for early AAV trials was Parkinson’s disease (PD).
Preclinical studies in a nonhuman a primate model of drug induced degeneration of the
substantia nigra demonstrated the efficacy of several gene therapy strategies
(Bankiewicz et al. 2006, Bartus et al. 2011, Björklund et al. 2000, Bohn et al. 1999,
Burns et al. 1983, Emborg et al. 2007, Hadaczek et al. 2010, Jarraya et al. 2009,
Muramatsu et al. 2002, Nagahara et al. 2009). Some were based on expression of
enzymes involved in neurotransmitter synthesis, aiming to augment dopamine
production in the substantia nigra in order to increase responsiveness to the dopamine
precursor L-dopa, or to increase GABA production in the subthalamic nucleus to restore
inhibitory signals to the basal ganglia that are disrupted in PD. Other strategies were
based on delivery of genes encoding neurotrophic factors, aiming to preserve remaining
dopaminergic neurons. The efficacy of these approaches in the primate model led to a
series of human trials. However, after more than 100 patients have been treated, there
6

has been little evidence of efficacy (Bartus, Weinberg, and Samulski 2014). While these
studies called into question the relevance of the drug-induced primate model of PD,
these early human studies provided important evidence for the safety of AAV delivery to
the brain. Further, PET imaging studies carried out in a trial for a vector expressing
aromatic amino acid decarboxylase (AADC) demonstrated transgene expression in the
brain for several years after treatment (Mittermeyer et al. 2012).

Thus while gene

therapy has not shown promise for the treatment of PD, the failed PD trials paved the
way for a variety of CNS gene therapy studies. Many of these were for rare genetic
diseases, and to date these are some of the only indications for which there has been
evidence of efficacy.

In trials for Canavan disease and aromatic amino acid

decarboxylase deficiency, treated patients have shown evidence of modestly attenuated
disease progression after intracranial AAV delivery (Janson et al. 2002, Leone et al.
2012, Hwu et al. 2012).

Intrathecal AAV Delivery
All trials of AAV-mediated CNS gene transfer to date have utilized multiple
intraparenchymal brain injections. While this delivery method demonstrated efficacy in
mouse models of many genetic disorders, there are two potential problems with
translating this approach to humans—scaling to the larger human brain (for diseases
that require whole-brain targeting), and the potential inflammatory response caused by
localized brain damage at the injection site. The issue of scaling is derived from the
distribution of transduction after intraparenchymal brain injection. Transgene expression
is generally limited to the cells immediately surrounding the injection site, although some
transduction can occur at more distal sites due to vector transport along axonal
projections (Vite et al. 2005, Castle et al. 2014). Some investigators have attempted to
7

increase vector distribution using convection-enhanced delivery, which employs
pressure gradients to drive the vector deeper into the brain parenchyma, although
improvements have been modest (Bankiewicz et al. 2000). In mouse models, even the
limited distribution that occurs after intraparenchymal injection results in transduction of
a significant portion of the brain. The problem with applying this approach to diseases in
which the entire CNS is affected has become apparent in studies of canine and feline
models of lysosomal storage diseases.

Even with the potential cross correction of

neighboring cells due to transgene secretion, these studies typically required at least 6
injections to correct storage pathology in a significant portion of the brain (Vite et al.
2005, Ciron et al. 2006). Scaling this method from the 30-70 g brain of a cat or dog to a
1.4 kg human brain would require more than 100 injections for equivalent distribution.
Since this is not feasible in humans, trials have instead pursued much more limited
injection strategies that cannot replicate the extent of brain transduction that has been
required for efficacy in animal models.
A second obstacle to translation of intraparenchymal vector injection to humans
is the potential local inflammation caused by the injection, and the resulting impact on
immune responses to the transgene product. Initiation of an adaptive immune response
requires an inflammatory “danger” signal to activate antigen presenting cells and recruit
lymphocytes, including CD8 T cells that can kill host cells presenting the target antigen,
as well as CD4 T cells which can activate B cells to produce antibodies against the
antigen. In the absence of inflammatory signals, reactive lymphocytes enter a default
pathway of anergy or tolerance to the foreign antigen. In the setting of gene therapy, it is
critical to avoid inflammatory signals at the time of vector delivery, as the newly
expressed non-self antigen could be a target for circulating B and T cells, and providing
8

a danger signal can initiate this response. This has been demonstrated in studies with
adenoviral vectors, in which the vector capsid provides an inflammatory signal so that
immunity is elicited against the transgene (Liu and Muruve 2003). With AAV vectors,
tolerance typically develops to the transgene product, apparently due to expression in
the absence of an inflammatory signal from the viral capsid or genome.

However,

providing the inflammatory signal by other means—such as local tissue destruction at
the time of injection—could result in transgene-specific immunity. This seems to have
occurred in early preclinical studies of AAV-mediated CNS gene therapy for two
lysosomal storage diseases. In dog models of these diseases, direct brain injection of
AAV vectors resulted in localized tissue damage followed by lymphocyte recruitment and
elimination of transduced cells (Ciron et al. 2006, Ellinwood et al. 2011).
Intrathecal injection presents a clear alternative to multiple direct brain injections.
CSF is produced by the choroid plexus in the ventricles and flows through the ventricular
system to the cisterna magna, then around the length of the spinal cord and the surface
of the brain. Thus vector injection into CSF could allow for widespread distribution in the
CNS with a single injection. However, intrathecal injection has not been widely pursued
as a method for delivery of biologics to the brain due to the belief that CSF is primarily
confined between the pia and arachnoid membranes, with little interaction with the brain
parenchyma (Papisov, Belov, and Gannon 2013). More recent studies have revealed
that in fact CSF flows deep into the brain via perivascular channels, and that even large
molecules can directly diffuse from these channels into the brain interstitial fluid (Iliff et
al. 2013, Iliff et al. 2012).

This new view of CSF flow is supported by studies of

intrathecal enzyme replacement therapy in animal models, which demonstrate that
enzyme delivered into CSF is readily taken up by the brain (Dickson, Ellinwood, et al.
9

2010, Dickson et al. 2009, Dickson, Hanson, et al. 2010, Dickson, Naylor, Mlikotic,
Victoroff, Chen, Passage, Le, et al. 2008, Kakkis, McEntee, et al. 2004, Vite et al. 2011).
These findings opened up the possibility of widespread delivery of proteins, or even viral
vectors, to the entire CNS with a single injection. This approach could potentially solve
the issue of scaling intraparenchymal injections to the human brain, and could have a
more favorable immunological profile by avoiding tissue damage and inflammation at the
time of injection.

Large animal models of MPS I
Evaluating intrathecal AAV delivery for MPS I requires animal models that
accurately reflect disease pathophysiology while also having the necessary size and
CNS anatomy to reasonably replicate intrathecal vector delivery and distribution in
humans. Mutations in the gene encoding IDUA resulting in a phenotype mimicking MPS
I have been described in transgenic mice, the Plott Hound dog, and the domestic
shorthair cat (Menon, Tieu, and Neufeld 1992, Shull et al. 1984, Haskins, Desnick, et al.
1979, Haskins, Jezyk, et al. 1979, He et al. 1999). MPS I mice have been generated
both as traditional knockouts and by targeting a common human mutation (W402X) to
the endogenous gene. The MPS I cat carries a 3 base pair in-frame deletion in the IDUA
gene, resulting in production of a protein missing a single aspartate residue that is
critical for substrate binding (He et al. 1999, Maita et al. 2013). The MPS I dog carries a
splice site mutation that results in the inclusion of the first intron in the mature mRNA,
creating an immediate stop codon (Menon, Tieu, and Neufeld 1992). All three animal
models exhibit the biochemical and histological abnormalities characteristic of MPS I,
including extensive storage lesions in the CNS. The neuropathology in the dog has been
the best characterized, and shows remarkably similarity to humans, with ectopic neurite
10

growth, axonal spheroids, and extensive ganglioside storage, providing strong evidence
for similar pathophysiology to the human disease.
The canine and feline models were used for all studies, as these species
appeared to much more closely recapitulate critical characteristics of MPS I patients.
Foremost among these is the sheer scale of the brain and CSF compartment. Delivery
of enzyme to cells throughout the brain is an essential obstacle for CNS directed gene
therapy for MPS I, which is dependent on both the diffusion of the vector in the CSF and
penetration into the brain parenchyma, as well as diffusion of the secreted enzyme from
transduced cells. In the small mouse brain (0.4 g) even very limited enzyme diffusion
from transduced cells near the injection site could result in significant correction of
storage lesions; however, in the 80 to 200-fold larger feline or canine brain, widespread
correction would depend on the same process of distribution through CSF that would be
essential for efficacy in humans.

These considerations of vector distribution and

similarities in brain pathology made the MPS I dog and cat appealing models for
evaluation of intrathecal AAV delivery for MPS I.

Goals of this dissertation
The following studies were carried out based on the central hypothesis that IT
AAV could achieve widespread targeting of cells in the CNS, and through crosscorrection, globally resolve storage pathology. Chapter 2 outlines the development of the
intrathecal approach for AAV delivery in nonhuman primates and initial findings
supporting the capacity of this method to achieve widespread transduction and evade
immune activation. These studies also delineate the critical importance of the site of
intrathecal injection for the distribution of vector in the CNS. Chapter 3 describes the
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application of this approach to MPS I in the feline model, including the impact on brain
pathology and the importance of humoral immune responses to the transgene.

In

Chapter 4 intrathecal AAV delivery was evaluated in MPS I dogs, which resulted in
strong antibody responses to IDUA. To circumvent the antibody response, a method
was developed to induce persistent antigen specific tolerance to IDUA. Subsequent
studies helped to define the impact of antibodies on CSF enzyme levels and disease
correction.

This study also presented a potential method for preventing immune

responses to gene and protein therapies for recessive diseases, an approach that was
confirmed in nonhuman primates. Finally in Chapter 5 this approach was utilized to
induce tolerance to the human IDUA enzyme in MPS I dogs to allow for evaluation of
intrathecal injection of a clinical candidate vector as a prelude to first in human trials.
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Chapter 2: Widespread Gene Transfer in the Central Nervous
System of Cynomolgus Macaques Following Delivery of AAV9
into the Cisterna Magna

Chapter 2 is adapted from: C. Hinderer, P. Bell, C. H. Vite, J.-P. Louboutin, R. Grant, E.
Bote, H. Yu, B. Pukenas, R. Hurst, J. M. Wilson, Molecular Therapy — Methods &
Clinical Development (2014).
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Abstract
Adeno-associated virus serotype 9 (AAV9) vectors have recently been shown to
transduce cells throughout the central nervous system of nonhuman primates when
injected into the cerebrospinal fluid (CSF), a finding which could lead to a minimally
invasive approach to treat genetic and acquired diseases affecting the entire CNS. We
characterized the transduction efficiency of two routes of vector administration into the
CSF of cynomolgus macaques— lumbar puncture, which is typically used in clinical
practice, and suboccipital puncture, which is more commonly used in veterinary
medicine. We found that delivery of vector into the cisterna magna via suboccipital
puncture is up to 100-fold more efficient for achieving gene transfer to the brain. In
addition, we evaluated the inflammatory response to AAV9-mediated GFP expression in
the nonhuman primate CNS. We found that while CSF lymphocyte counts increased
following gene transfer, there were no clinical or histological signs of immune toxicity.
Together these data indicate that delivery of AAV9 into the cisterna magna is an
effective method for achieving gene transfer in the CNS, and suggest that adapting this
uncommon injection method for human trials could vastly increase the efficiency of gene
delivery.

Introduction
Gene therapy using AAV vectors has enormous potential to treat acquired and
congenital diseases affecting the central nervous system (CNS). Numerous studies in
murine disease models have demonstrated the efficacy of AAV-mediated gene transfer
in the brain, and initial human studies have shown an excellent safety profile (Haurigot et
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al. 2013, Wolf et al. 2011, Tardieu et al. 2013, Kaplitt et al. 2007, McPhee et al. 2006).
These pioneering clinical trials were carried out using multiple direct injections of the
vector into the brain parenchyma, a strategy which has been shown in preclinical studies
to achieve efficient gene transfer to cells surrounding the injection site (Vite et al. 2005).
However, treatment of diseases affecting cells throughout the CNS will ultimately
necessitate a delivery strategy capable of widespread transduction. Simply increasing
the number of intra-parenchymal injections is not feasible, as even the most promising
large animal studies have required at least 4 injection sites, which would translate to
more than 100 injections in an adult human (Vite et al. 2005, McCurdy et al. 2014).
Intravascular (IV) delivery of AAV serotype 9, which can traverse the blood-brain barrier,
has been proposed as an alternative approach to achieve widespread transduction in
the CNS (Bevan et al. 2011). While IV delivery is extremely effective in mice, in larger
animals transduction in the CNS has been much more restricted (Gray et al. 2011,
Samaranch et al. 2012). This approach is further limited by the extremely large doses
required to achieve transduction in the brain and the resulting high off-target
transduction of peripheral organs (Bevan et al. 2011, Gray et al. 2011).
Several groups have recently reported that delivery of AAV serotypes 7 and 9
into the cerebrospinal fluid (CSF) of nonhuman primates can effect transduction of both
neurons and glia throughout the brain and spinal cord (Samaranch et al. 2012,
Samaranch, Salegio, et al. 2013, Gray et al. 2013). This represents a critical advance in
the field of CNS gene therapy. It may now be possible not only to achieve gene transfer
throughout the CNS in humans, but to do so with a single minimally invasive injection.
Access to the subarachnoid CSF is routinely achieved by lumbar puncture in clinical
practice for diagnostic purposes and for administration of medications. Although less
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common, access can also be achieved at the level of the cisterna magna by suboccipital puncture. Intrathecal AAV delivery therefore represents a relatively low-risk
delivery strategy that could be readily translated to the clinic.
In order to advance this approach toward clinical trials, we performed nonhuman
primate studies to evaluate the efficiency of two minimally invasive delivery
approaches—lumbar

puncture

and

suboccipital

puncture—for

achieving

vector

distribution throughout the brain and spinal cord. One previous study reported that both
strategies result in transgene expression in the brain, but did not quantitatively compare
vector distribution (Gray et al. 2013). Based on our findings we estimate that suboccipital puncture is 10 to 100-fold more efficient for brain transduction, making this
approach far more promising for clinical use.
In addition, we performed detailed evaluation of histological markers of
inflammation in the CNS of treated animals. Several studies have found intrathecal
delivery of AAV9 to be safe in nonhuman primates and other species, although one
group has reported that macaques treated with a vector carrying a GFP transgene
experienced neurological deficits associated with histological evidence of an
inflammatory response (Samaranch et al. 2014).

We found that treated animals

exhibited no clinical or histological abnormalities, although CSF lymphocytes were
elevated in some animals. Overall our data suggest that intrathecal AAV injection by
suboccipital puncture could serve as a useful gene transfer method for the treatment of
neurological disease.
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Materials and Methods
Animals: All study protocols were approved by the institutional animal care and use
committee of the University of Pennsylvania. Six adult female cynomolgus macaques
were used in this study. These animals were not pre-screened for AAV9 neutralizing
antibodies. An additional female rhesus macaque was used for the intravenous delivery
experiment.

This animal was prescreened for AAV9 neutralizing antibodies as

previously described(Wang et al. 2011).
Lumbar

vector

injection:

Animals

were

anesthetized

using

IM

ketamine/dexmedetomidine. The hair over the lumbar spine was shaved and the skin
sterilely prepped. To widen the intervertebral space the spine is flexed slightly, drawing
the animal’s hind limbs forward toward the umbilicus. A spinal needle was inserted into
the center of the L3-L4 intervertebral space just behind the anterior vertebral spinous
process. Needle placement was confirmed by CSF return. CSF (1 mL) was collected,
then a syringe containing vector (1 mL diluted in PBS) was attached to the spinal needle
through a flexible linker. Vector was slowly injected by hand over one minute. After
injection placement was again confirmed by CSF return. The needle was removed and
direct pressure applied to the puncture site.
Intracisternal

vector

injection:

Animals

were

anesthetized

using

IM

ketamine/dexmedetomidine. The hair over the back of the head and neck was shaved
and the skin sterilely prepped. The occipital protuberance at the back of the skull and the
wings of the atlas (C1) were palpated, and a needle was inserted midway between them.
Needle placement was confirmed by CSF return. CSF (1 mL) was collected, then a
syringe containing vector (1 mL diluted in PBS) was attached to the needle through a
flexible linker.

Vector was slowly injected by hand over one minute. After injection
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placement was again confirmed by CSF return. The needle was removed and direct
pressure applied to the puncture site.
Vector Production: Single-stranded AAV9 vectors were produced by triple transfection
of 293 cells and purified by iodixanol gradient centrifugation as previously
described(Wang et al. 2011).
Quantitative PCR: Vector genomes were quantified in tissue samples by Taqman PCR
as previously described(Wang et al. 2011).
Histology: Brains were divided into left and right hemisphere. The right half was sliced,
fixed in formalin overnight, and embedded in paraffin for the preparation of H&E stained
sections and for immunostaining. Slices from the left half were formalin-fixed and
processed for GFP detection as described below. PCR samples for vector biodistribution
studies were also retrieved from the left brain half prior to fixation. Tissues from spinal
cord was collected from cervical, thoracic, and lumbar regions and processed for paraffin
and cryosections as described for the brain.
Hematoxylin and eosin staining (H&E): H&E staining was performed on 6 µm paraffin
sections according to standard protocols.
GFP fluorescence: Brain slices were fixed overnight in formalin, equilibrated sequentially
in 15% and 30% sucrose in PBS, and frozen in OCT embedding medium for the
preparation of cryosections for visualization of direct GFP fluorescence. Sections were
mounted in Vectashield containing DAPI (Vector Laboratories, Burlingame, CA) as
nuclear counterstain.
Immunohistochemistry for GFP: Sections were deparaffinized through an ethanol and
xylene series, boiled in a microwave for 6 min in 10mM citrate buffer (pH 6.0) for antigen
retrieval, treated sequentially with 2% H2O2 (15 min), avidin/biotin blocking reagents (15
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min each; Vector Laboratories), and blocking buffer (1% donkey serum in PBS + 0.2%
Triton for 10 min) followed by incubation with primary (1h) and biotinylated secondary
antibodies (45 min; Jackson Immunoresearch, West Grove, PA) diluted in blocking
buffer. As primary antibodies served a rabbit serum or a chicken antibody against GFP
(both from Abcam, Cambridge, MA; diluted 1:1000) which both yielded similar results. A
Vectastain Elite ABC kit (Vector Laboratories) was used according to the manufacturer's
instructions with DAB as substrate to visualize bound antibodies as brown precipitate.
Sections were slightly counterstained with hematoxylin to show nuclei. In some
experiments hematoxylin counterstaining or antibodies were omitted as described in the
text.
Immunofluorescence: Immunostaining was performed on sections from formalin-fixed
paraffin-embedded tissue samples. Sections were deparaffinized and treated for antigen
retrieval as described above, then blocked with 1% donkey serum in PBS + 0.2% Triton
for 15 min followed by sequential incubation with primary (1 h) and fluorescence-labeled
secondary antibodies (45 min) diluted in blocking buffer. Primary antibodies used were
goat antibodies against GFAP (Novus Biologicals, Littleton, CO; 5µg/ml working
concentration) and Iba1 (Abcam, 1:200), and TRITC-labeled donkey anti-goat (Jackson
Immunoresearch, 1:100) served as secondary antibody.
Morphometric analyses: To quantify astrocytes (GFAP-positive cells) and microglia
(Iba1-positive cells), 15 images were taken from immunostained brain sections per
animal with a 20x objective showing the area directly below the cerebral cortex surface.
Positive cells were counted manually and averaged for each animal. Brain tissues from
two cynomolgus macaques from an unrelated study that had received AAV2.TGB.EPO
intravenously and showed negligible vector genome copy numbers in the brain (below
1x10-4 gc/cell) served as controls (Gao et al. 2006).
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For the quantification of transduced motor neurons, spinal cord sections were stained
with Neurotrace red fluorescent Nissl stain (Life Technologies, Grand Island, NY)
according to the manufacturer's instructions and images were taken at low magnification
(4x objective) showing GFP expression and Neurotrace staining. Between three to five
images were taken from the ventral area of each spinal cord region (cervical, thoracic,
lumbar) to cover several sections per animal. ImageJ software (Rasband W. S., National
Institutes of Health, USA; http://rsb.info.nih.gov/ij/) was used to first threshold and then
select all Neurotrace-positive cells with a minimum pixel number of 175 reflecting a
threshold diameter of approximately 25 µm. To determine the percentage of sizeselected neurons that were GFP-positive, all selected neurons and those that were GFPpositive were counted for each image.

Results
Intracisternal delivery achieves broader vector distribution in the CNS
We treated six cynomolgus macaques with an intrathecal injection of a singlestranded AAV9 vector expressing GFP from either the cytomegalovirus (CMV) or
chicken beta-actin (CB) promoter (Table 2-1). Four of the animals were injected via suboccipital puncture; two were treated via lumbar puncture. There were no adverse clinical
events during the course of the study. All animals were sacrificed 14 days after injection
for histological analysis.
Vector distribution was evaluated in CNS and peripheral tissues by quantitative
PCR (Figure 2-1). All animals treated by sub-occipital puncture exhibited substantial
vector deposition in the brain and spinal cord, with up to one vector genome per cell in
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most regions.

Animals treated by lumbar puncture had approximately 10-fold lower

gene transfer throughout the spinal cord, and up to 100-fold less in the brain.

In

contrast, both groups had similar distribution to peripheral organs. Vector copy numbers
were quite high in liver and spleen, indicating significant vector escape to the peripheral
circulation.
As previous studies have demonstrated the ability of AAV9 to transduce cells
within the CNS following intravascular injection, we treated one rhesus macaque
intravenously to compare the efficiency of this approach to intrathecal injection (Figure 21).

Despite the use of a high vector dose (2 x 1013 GC/kg) and the absence of

detectable neutralizing antibodies to AAV9 in this animal, vector distribution to the CNS
was substantially lower than that achieved at 4-8 fold lower doses via cisternal injection.
Due to the low CNS gene transfer efficiency observed in this animal we did not explore
this route of administration further.
GFP false positives complicate assessment of transgene expression in the CNS
We initially attempted to quantify GFP expressing cells in the CNS by
immunohistochemistry (IHC), as other groups have previously utilized this method to
measure GFP expression in the nonhuman primate CNS (Gray et al. 2013, Samaranch,
Salegio, et al. 2013). We identified what appeared to be a large number of GFP positive
cells throughout the CNS of treated macaques (Figure 2-7, A and C). However, we also
detected a similar staining pattern in some negative control brain tissues from animals
that had not received a GFP expressing vector (Figure 2-7, B and D). The false-positive
neurons appeared dark on H&E sections, a property consistent with the “dark neuron”
artifact that has long been described in brain tissue, particularly when prepared by
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immersion fixation (Jortner 2006). The high affinity of these cells for H&E did not explain
their dark color in IHC sections, as the cells still appeared to stain positive when the
hematoxylin counterstain was omitted from IHC sections (Figure 2-7 E, G). Omission of
the primary antibody and both primary and secondary antibodies in combination
demonstrated that the false-positive neurons did not exhibit endogenous peroxidase
activity, but instead nonspecifically bound antibodies used for IHC (Figure 2-7 F, H).
Because these false positive neurons were detected sporadically in various negative
control tissues, we determined that IHC could not be used to reliably detect GFP
expression in brain samples.
In order to overcome the problem of GFP false positive cells, we instead used
direct GFP fluorescence to measure expression.

We initially avoided this method

because many cells in the CNS exhibit auto-fluorescence. We found that we could
account for these fluorescence false positives by overlaying images captured in a red
fluorescence channel, as GFP is detectable only in the green channel whereas autofluorescent material appears across several channels (Figure 2-8). We therefore used
direct GFP fluorescence verified by overlay with a red channel image to identify GFP
positive cells. Using this method, GFP expressing cells were detected in treated animals
but not in any control tissues. All subsequent analyses were carried out using this
approach, and red channel images are shown for all cases in which auto-fluorescence
was observed.
Intracisternal AAV9 transduces cells throughout the brain and spinal cord
Consistent with the high vector distribution to the brain in animals treated by
intra-cisternal injection, GFP expression was observed in clusters of cells throughout
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most regions of the brain, which were interspersed with untransduced regions (Figure 23).

Costaining with a fluorescent Nissl stain (NeuroTrace) and antibodies against

astrocyte and microglial markers (GFAP and Iba1) revealed that virtually all GFP positive
cells were neurons (Figure 2-3) although rare transduced astrocytes were also detected
(Figure 2-3, l). Virtually no GFP positive cells were detected in the cerebrum of animals
treated by lumbar puncture. In the spinal cord, GFP expression was prominent in the
ventral horns of animals treated by intracisternal injection (Figure 2-4a).

High

magnification images show that these transduced cells were primarily the large lower
motor neurons (Figure 2-4b). These cells were heavily transduced in the thoracic and
lumbar segments of animals treated by intracisternal injection (Figure 2-4, Table 2-2).
There were also a small number of transduced motor neurons in the cervical spinal cord
of these animals. Transduced spinal cord cells were rare in the animals treated by
lumbar administration (Table 2-2). The macaque treated with a high dose of intravenous
AAV9 exhibited no GFP expression in the cerebrum or cerebellum, although several
transduced neurons were observed in the thoracic and lumbar spinal cord (Figure 2-5,
Table 2-2).
Intrathecal AAV9 does not induce an inflammatory response in the nonhuman primate
brain
As one previous study reported evidence of inflammation in the cerebrum of
nonhuman primates following intrathecal delivery of an AAV9 vector expressing GFP,
we analyzed the brains of all treated animals for signs of inflammation (Samaranch et al.
2014).

No untreated animal tissues were available for histology controls, so we

analyzed brains from two cynomolgus macaques that were treated with an intravenous
injection of an AAV serotype 2 vector expressing erythropoietin from a liver specific
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promoter; these animals were previously found to have virtually no vector deposition in
the brain (Gao et al. 2006). Histopathology showed no evidence of cellular infiltrates in
the brain parenchyma or in the meninges or perivascular spaces in any of the treated
animals (Figure 2-9). We quantified cells expressing GFAP, an intermediate filament
protein that is upregulated in astrocytes in the setting of inflammation. There were no
differences in the frequency of GFAP positive cells in the brains of treated animals and
controls (Figure 2-9, Table 2-3). We also quantified microglia by Iba1 staining. The
frequency of microglia was normal in all animals, and microglia exhibited morphology
characteristic of a resting rather than an activated state (Figure 2-9, Table 2-3).
Although there was no evidence of inflammation in brain tissue, we did observe a
moderate lymphocytic pleocytosis in the CSF of two of the animals that were treated with
intracisternal injection, which correlates with the higher CNS transduction in these
animals (Table 2-4).

Discussion
As the first gene transfer strategy capable of achieving high levels of transduction
throughout the CNS in large animals, intrathecal AAV delivery could greatly expand the
applications of gene therapy in neurological disease.

Intrathecal AAV injection is a

particularly attractive strategy because of the relative ease of accessing the intrathecal
space compared to the invasive neurosurgical procedure required for intraparenchymal
injection. We found that vector delivery into the CSF at the level of the cisterna magna
is far more efficient than lumbar intrathecal injection for gene transfer to the brain and
spinal cord. It is interesting that the level of CSF access had such a profound effect on
vector distribution, as previous work has shown that a protein infused into the lumbar
CSF is distributed throughout the CNS (Calias et al. 2012).
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This may therefore

represent a property of the viral particle, and not reflect the behavior of other substances
delivered into the intrathecal space. One potential explanation is that the vector quickly
binds to cell surfaces, which would allow for wide distribution from the rapidly dispersing
cisternal CSF, but not from the slower moving CSF lying inferior to the spinal cord in the
lumbar cistern. Vector distribution in the CSF could be influenced by additional factors—
such as the volume and formulation of the injection—which should be evaluated in future
studies.

Translation of this approach to humans may also benefit from further

investigation of the impact of total CSF volume and cisternal volume on vector
distribution, as these factors vary between species and among humans (Whitney et al.
2013).
Given the superior transduction efficiency achieved by vector delivery into the
cisterna magna, it will be critical to develop a safe means of performing this procedure in
patients. Though cisternal injection is commonly performed in nonhuman primates and
other animals, it is infrequently utilized in clinical practice. Suboccipital puncture of the
cisterna magna was first described in humans in 1920 as a technique for introduction of
air or contrast material for diagnostic studies (Ayer 1920). Traditional indications for
cisternal puncture have also included CSF sampling. The suboccipital puncture has
largely been supplanted by noninvasive diagnostic studies including CT and MRI and by
CSF sampling from lower levels of the spinal canal, such as between the first and
second cervical vertebrae or between lumbar vertebrae below the level of the spinal
cord, techniques which are associated with lower rates of complications. The most
serious complications associated with cisternal puncture include inadvertent injury to
vascular structures with resultant hemorrhage as well as brainstem injury.

A 1929

review of the literature identified 6 reported deaths in 2019 reported procedures in 535
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patients (Ayer 1920). These authors also identified 9 additional cases of medullary
injury, noting however that in skilled hands the procedure should not be considered
dangerous (Saunders and Riordan 1929). In 1973, Keane again reviewed the literature
finding that subarachnoid hemorrhage was the most common major complication of
cisternal puncture, with at least 30 reported fatalities (Keane 1973). He noted that other
serious complications resulted from direct puncture of brain substance. In 1989, Ward et
al. evaluated cisternal puncture in cadavers, finding that “tenting” of the dura at the site
of needle penetration could result in deeper than expected penetration prior to entry into
the subarachnoid space (Ward, Orrison, and Watridge 1989).
The few more recent publications available on suboccipital puncture suggest that
modern day imaging equipment may improve safety by enhancing visualization of critical
structures during the procedure. A recent report described better visualization of critical
structures during a cisternal puncture by performing a contrast enhanced CT
immediately prior to needle insertion (Pomerantz 2005). Axial and sagittal contrast
enhanced CT images (Figure 2-6) would allow for visualization of the entire needle path,
which courses in the midline between the base of the occiput and the first vertebra to the
cisterna magna. Contrast enhanced CT allows for visualization of the local vascular
structures, particularly the posterior inferior cerebellar artery (PICA), which has
historically been the source of bleeding in reported cases of subarachnoid hemorrhage
following suboccipital puncture.

Employing imaging with suboccipital puncture could

also be useful for preventing damage to the medulla, a previously reported complication
resulting from advancing the needle beyond the cisterna magna. The use of more
sophisticated integrated navigation systems, like the Philips PercuNav system, may also
provide an additional layer of safety by allowing real time needle visualization during the
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procedure.

We therefore believe that suboccipital puncture, though uncommonly

utilized, could represent a safe and feasible vector delivery approach for clinical use.
Consistent with previous studies, we observed efficient transduction of motor
neurons in the thoracic and lumbar spinal cord following intrathecal AAV9 delivery. We
found that transduction in the cerebrum, however, was much more diffuse, consisting of
patches of GFP expressing cells. The transduction efficiency we observed in the brain
was much lower than that reported by others, particularly following lumbar intrathecal
delivery (Gray et al. 2013). Given the potential for immunohistochemistry to produce
GFP false positive cells in the CNS, it is likely that this artifact may have contributed to
exaggerated transduction efficiencies in some reports. This possibility is supported by
quantitive PCR data, which in one previous study show approximately one vector
genome present per 100 cells in the brain—similar to our results for lumbar delivery—
which would preclude transduction of the nearly 50 percent of cells identified as GFP
positive by immunohistochemistry in that study (Gray et al. 2013). Other studies of
intrathecal AAV9 injection have demonstrated a pattern of brain transduction more
similar to that described here (Samaranch et al. 2012, Samaranch, Salegio, et al. 2013).
Clinical trials of intraparenchymal injection of AAV serotypes 2 and rh.10 have
demonstrated excellent tolerability despite the inherent invasiveness of this delivery
method(Kaplitt et al. 2007, McPhee et al. 2006, Tardieu et al. 2013). Several studies of
intrathecal AAV9 administration in nonhuman primates have indicated that it is similarly
well tolerated.

However, one study reported that macaques treated with intrathecal

AAV9 expressing GFP developed neurologic deficits 2-3 weeks following vector
administration (Samaranch et al. 2014). These animals also exhibited histological signs
of inflammation in the brain, including MHC class II upregulation and microglial
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activation. This was presumed to be due to an immune response against the foreign
GFP transgene. We did not identify similar clinical or histological findings in any treated
animals. It is possible that we did not observe the same phenomenon due to our shorter
follow up period (two vs three weeks). However, the same group previously reported
treating four macaques with intrathecal AAV9, as well as two with AAV7, both
expressing GFP, without any complications during the same three week follow up period
(Samaranch et al. 2012, Samaranch, Salegio, et al. 2013). Likewise, another group
reported no adverse events or histological abnormalities after four weeks of follow up in
10 macaques treated with intrathecal AAV9 expressing GFP (Gray et al. 2013).

It

therefore appears that this isolated observation of an inflammatory response following
intrathecal AAV9 delivery was unlikely due to the vector itself, though future studies
should continue to monitor subjects for such a response. Although we did not observe
any clinical or histological abnormalities, we did observe elevated CSF lymphocytes in
two of the treated animals. This suggests that there may be some degree of immune
activation by the vector or GFP transgene, although we have not observed any clinical or
histological consequences of this response.
Our results demonstrate that delivery of an AAV9 vector into the cisterna magna
is an effective approach to achieve transduction of cells throughout the nonhuman
primate CNS. The excellent safety and feasibility of this route of administration should
enable rapid deployment into the clinic for a wide range of diseases affecting the CNS.
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Figure 2-1. AAV9 biodistribution following intrathecal delivery in nonhuman primates
12

AAV9 was administered to six cynomolgus macaques at doses of 2.5 – 5 x 10

GC/kg

by injection into the cisterna magna (n = 4) or the lumbar subarachnoid space (n = 2).
13

An additional animal was treated intravenously with a high dose (2 x 10

GC/kg) of

AAV9. All animals were sacrificed two weeks after injection and vector genomes were
quantified in tissue samples by Taqman PCR.
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Figure 2-2. Transduction throughout the brain following intracisternal AAV9 delivery
12

AAV9 was administered to six cynomolgus macaques at doses of 2.5 – 5 x 10

GC/kg

by injection into the cisterna magna (n = 4) or the lumbar subarachnoid space (n = 2).
Brain sections from animals treated by intracisternal injection (a-i) and those treated by
lumbar puncture (j-l) were imaged for native GFP fluorescence. Counterstain is DAPI (a,
e, i-l). All images shown were negative for fluorescence in the red channel. (a) Meninges
(b-d) Cerebral cortex (e) Dentate gyrus (f) Thalamus (g, h) Cerebellum with large
Purkinje cells. (i) Cerebellum with transduced neurons in granular layer. (j-l). Direct GFP
fluorescence in meninges (j), cerebral cortex (k), and cerebellum (l) after treatment by
lumbar puncture. Scale bar: 100 µm (f, i, j), 200 µm (a, d, e, g, h, k, l), 500 µm (b, c).
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Figure 2-3. Predominantly neuronal transduction of intrathecal AAV9
Cortical brain sections from animals treated by intracisternal injection were imaged for
native GFP fluorescence (a, e, i, m). Images are overlaid with a fluorescent Nissl stain
(NeuroTrace) for detection of neurons (b, c, d), GFAP immunostaining for astrocytes (f,
g, h, j, k, l), or Iba1 staining for microglia (n, o, p). Counterstain is DAPI (d, h, l, p). Scale
bar = 50 µm.
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Figure 2-4. Spinal cord transduction following intrathecal AAV9 administration by
intracisternal or lumbar injection
Direct fluorescence images were captured for three spinal cord segments from all
treated animals. Low magnification images show transduction primarily in the ventral
gray matter (a). High magnification images of the ventral horn demonstrate transduction
primarily of large neurons in the thoracic and lumbar segments, with occasional
transduced cells in the cervical segment (white arrow). Scale bar: 1 mm. (b). As
autofluorescence was observed in some spinal cord sections, an overlay of the red and
green channels is shown to identify false positive GFP signal (yellow). Scale bar: 200
µm.
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Figure 2-5. Limited CNS transduction following intravascular AAV9 delivery
A rhesus macaque was treated intravenously with an AAV9 vector (2 x 10
expressing GFP.

13

GC/kg)

Sections were imaged for native GFP fluorescence from cerebral

meninges (a), cortex (b) and cerebellum (c). Some GFP expressing cells (arrows) were
noted in the thoracic spinal cord (d). GFP expression was confirmed by absence of
fluorescence in the red channel (e). In contrast to the CNS, peripheral organs including
liver were heavily transduced (f). Counterstain is DAPI (a-c). Scale bar: 200 µm.
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Figure 2-6. Evaluation of anatomic landmarks for suboccipital puncture
Axial (a) and sagittal (b) contrast enhanced CT images illustrating key structures to
identify when performing a suboccipital puncture.
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Figure 2-7. Detection of false positive GFP expressing cells by immunohistochemistry
Sections from cerebrum and cerebellum from the AAV9 treated animals (a and c) and an
untreated control (b and d) were stained with a chicken anti-GFP antibody followed by a
horseradish peroxidase labeled anti-chicken secondary. In order to identify the cause of
nonspecific staining, sequential brain sections from an untreated animal were stained
with H&E (e), primary and secondary antibodies for GFP detection as well as
hematoxylin counterstain (f), IHC antibodies without counterstain (g), or hematoxylin and
peroxidase substrate only (h). Scale bar: 100 μm.
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Figure 2-8. Differentiating GFP fluorescence from autofluorescence in spinal cord
Fixed frozen sections of a spinal cord expressing GFP (A-C) or not expressing GFP (DF) were imaged by fluorescence microscopy in both red and green channels. The
overlaid images (C and F) distinguish autofluorescent material by its broader emission
spectrum, which results in equal red and green channel signal. Scale bar: 200 μm.
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Figure 2-9. Absence of an inflammatory response following intrathecal delivery of AAV9
expressing GFP
Brain sections from intrathecal AAV9 treated animals and control animals were stained
with H&E, and immunostained for the astrocyte marker GFAP and the microglial marker
IbaI. Scale bar: 100 μm.
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Table 2-1. Summary of study subjects
Weight
Animal #

ROAA

Vector

Dose

Sex

Age

(kg)
17

CM

AAV9.CMV.eGFP

5 x 1012 GC/kg

3.60

F

8 years

18

CM

AAV9.CB7.eGFP

5 x 1012 GC/kg

3.85

F

8 years

20

CM

AAV9.CB7.eGFP

2.5 x 1012 GC/kg 5.40

F

8 years

21

CM

AAV9.CB7.eGFP

2.5 x 1012 GC/kg 8.75

F

8 years

04

L

AAV9.CB7.eGFP

2.5 x 1012 GC/kg 4.25

F

8 years

05

L

AAV9.CB7.eGFP

2.5 x 1012 GC/kg 4.85

F

8 years

49

IV

AAV9.CMV.eGFP

2.0 x 1013 GC/kg

F

8 years

3.30

A. L = lumbar injection, CM = cisterna magna, IV = intravenous
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Table 2-2. Quantification of transduced motor neurons throughout the spinal cord
Animal #

ROAA

Promoter

Percent GFP+ motor neuronsB
Cervical

Thoracic

Lumbar

17

CM

CMV

ND

10.7 ± 11.4

14.5 ± 17.6

18

CM

CB

0±0

8.4 ± 2.3

20.3 ± 4.9

20

CM

CB

0.3 ± 0.6

25.1 ± 17.0

19.3 ± 11.0

21

CM

CB

1.5 ± 2.1

48.0 ± 15.6

38.2 ± 23.4

04

L

CB

0.3 ± 0.6

0±0

0.6 ± 1.3

05

L

CB

0±0

1.7 ± 2.9

2.6 ± 5.2

49

IV

CMV

0±0

7.7 ± 10.5

0.2 ± 0.5

A. L = lumbar injection, CM = cisterna magna, IV = intravenous
B. Mean ± standard deviation in four fields
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Table 2-3. Quantification of GFAP and IbaI positive cells in brain sections
Animal #

ROAA

Vector

GFAPB

IbaI

17

CM

AAV9.CMV.eGFP

15.1 +/- 12

4.6 +/- 1.6

18

CM

AAV9.CB7.eGFP

14.1 +/- 8.4

4 +/- 1.6

20

CM

AAV9.CB7.eGFP

11.8 +/- 9.2

4.7 +/- 1.7

21

CM

AAV9.CB7.eGFP

19.6 +/- 16

4.8 +/- 0.3

04

L

AAV9.CB7.eGFP

9.6 +/- 11.2

4.7 +/- 1.4

05

L

AAV9.CB7.eGFP

16.5 +/- 19

4.2 +/- 1.8

80

IV

AAV2.TBG.EPO

14.6 +/- 7.5

9.2 +/- 2.9

86

IV

AAV2.TBG.EPO

12.7 +/- 3.8

8.4 +/- 1.9

A. L = lumbar injection, CM = cisterna magna, IV = intravenous
B. Mean number of positive cells ± standard deviation in 15 fields
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Table 2-4. CSF analysis
Nucleated Cells/µl

Total Protein (mg/dL)

Animal #

Treatment

ROAA

Day 0

Day 14

Day 0

Day 14

04

AAV9.CB7.eGFP

L

1

ND

12

ND

05

AAV9.CB7.eGFP

L

0

2B

15

25B

20

AAV9.CB7.eGFP

CM

2

41C

11

25

21

AAV9.CB7.eGFP

CM

4

13C

20

14

A. L = lumbar injection, CM = cisterna magna
B. traumatic tap; RBC count = 2090/µL
C. >70% lymphocytes

41

CHAPTER 3: Intrathecal gene therapy corrects CNS pathology in
a feline model of mucopolysaccharidosis I

Chapter 3 is adapted from: C. Hinderer, P. Bell, B. L. Gurda, Q. Wang, J.-P. Louboutin,
Y. Zhu, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. Wang, M. E. Haskins, J. M.
Wilson, Molecular therapy (2014).
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Abstract
Enzyme replacement therapy has revolutionized the treatment of the somatic
manifestations of lysosomal storage diseases (LSD), although it has been ineffective in
treating central nervous system (CNS) manifestations of these disorders. The
development of neurotrophic vectors based on novel serotypes of adeno-associated
viruses (AAV) such as AAV9 provides a potential platform for stable and efficient
delivery of enzymes to the CNS. We evaluated the safety and efficacy of intrathecal
delivery of AAV9 expressing α-l-iduronidase (IDUA) in a previously described feline
model of mucopolysaccharidosis I (MPS I). A neurological phenotype has not been
defined in these animals, so our analysis focused on the biochemical and histological
CNS abnormalities characteristic of MPS I. Five MPS I cats were dosed with AAV9
vector at 4-7 months of age and followed for 6 months. Treated animals demonstrated
virtually complete correction of biochemical and histological manifestations of the
disease throughout the CNS. There was a range of antibody responses against IDUA in
this cohort which reduced detectable enzyme without substantially reducing efficacy;
there was no evidence of toxicity. This first demonstration of the efficacy of intrathecal
gene therapy in a large animal model of a LSD should pave the way for translation into
the clinic.

Introduction
Mucopolysaccharidosis type I (MPS I, Hurler, Scheie, Hurler-Scheie syndromes)
is a recessively inherited disease caused by deficiency of a ubiquitous lysosomal
enzyme, α-l-iduronidase (IDUA), which is required for the degradation of the
glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. Accumulation of
these undegraded lysosomal substrates results in widespread tissue pathology, often
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characterized by skeletal deformities, cardiac and pulmonary disease, upper airway
obstruction, and in some cases, progressive neurological disease (Xing et al. 2014).
The central nervous system manifestations of MPS I vary, with profound developmental
decline occurring in early childhood in severely affected patients, while those with a
more mild phenotype often maintain normal intelligence(Kachur and Del Maestro 2000,
Taccone et al. 1993, Vijay and Wraith 2005, Zafeiriou and Batzios 2013, Furukawa et al.
2011, Ahmed et al. 2014).
sometimes

face

serious

However, even the patients with attenuated disease
neurological

complications

such

as

communicating

hydrocephalus, as well as spinal cord compression secondary to GAG storage in the
meninges.
The currently available treatments for MPS I include bone marrow transplantation
(BMT) and intravenous enzyme replacement therapy (ERT). Both modalities exploit the
observation that the mannose-6-phosphate receptor, which is responsible for sorting
lysosomal proteins from the trans-Golgi, is also expressed at the cell surface, allowing
for receptor-mediated uptake and lysosomal trafficking of IDUA infused intravenously or
secreted from donor-derived leukocytes following BMT (Dahms, Lobel, and Kornfeld
1989),(Kakkis et al. 1994).

While both ERT and BMT have demonstrated efficacy

against many of the somatic features of MPS I, only BMT is believed to alter the course
of CNS disease, presumably through IDUA secretion by donor derived cells that migrate
into the CNS(Aldenboven, Boelens, and de Koning 2008). Despite the promise of this
approach, BMT has been associated with engraftment rates as low as 50% and mortality
rates in excess of 10% in MPS I patients(Aldenboven, Boelens, and de Koning 2008).
Studies in the canine model of MPS I and small clinical trials have indicated that it may
be possible to instead achieve IDUA delivery throughout the CNS using intrathecal
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injection of the enzyme, which would allow for distribution via the cerebrospinal
fluid(Chen et al. 2011, Dickson, Ellinwood, et al. 2010, Dickson, Naylor, Mlikotic,
Victoroff, Chen, Passage, and Le 2008, Dickson et al. 2009, Dickson, Hanson, et al.
2010, Dickson, Naylor, Mlikotic, Victoroff, Chen, Passage, Le, et al. 2008, Kakkis,
McEntee, et al. 2004, Munoz-Rojas et al. 2008).

While intrathecal ERT provides

important proof of principle for achieving enzyme distribution in CNS via the CSF, it does
not represent a practical treatment approach due to the need to repeatedly access the
CSF for enzyme delivery for the lifetime of the patient. This leaves a significant unmet
need for a safe and effective long-term treatment for the CNS manifestations of MPS I.
Gene therapy offers an attractive alternative to BMT and intrathecal ERT for
targeting the CNS in MPS I. Gene transfer to the brain using adeno-associated viral
(AAV) vectors has been found safe in multiple human trials, and delivery of the
therapeutic transgene to quiescent cells within the CNS could provide a permanent
source of secreted enzyme, obviating the need to repeatedly access the CSF (Mandel
and Burger 2004, McPhee et al. 2006, Mittermeyer et al. 2012, Kaplitt et al. 2007). In
murine MPS models, CNS-directed AAV gene transfer has demonstrated complete
correction of tissue lesions and improvements in disease-specific behavioral phenotypes
(Wolf et al. 2011, Haurigot et al. 2013). The primary obstacle to this approach has been
translation to large animal models.

Direct intra-parenchymal brain injection of AAV

vectors results in transgene expression constrained to the area surrounding the injection
site, with histological correction limited to the adjacent tissue (Vite et al. 2005). Although
studies in both canine and feline models of lysosomal enzyme deficiencies have shown
that this limitation can be overcome using multiple vector injections, this strategy is not
readily scalable to the human brain (Vite et al. 2005, Ciron et al. 2006). Further, intra45

parenchymal injections have been shown to induce a local inflammatory response that
can be accompanied by elimination of transduced cells (Ciron et al. 2006).

A potential

alternative delivery approach has been highlighted by recent studies of intrathecal AAV
delivery, which show that in dogs, cats and nonhuman primates, an AAV9 vector
delivered into the CSF transduces glial and neuronal cells throughout the brain and
spinal cord (Gray et al. 2013, Haurigot et al. 2013, Bucher et al. 2014a). This potential
to transduce cells across the neuraxis in a large animal via a single minimally invasive
injection could radically transform the therapeutic potential of AAV-mediated gene
therapy for CNS disease. We hypothesized that this capacity of intrathecal AAV9 to
effect such widespread CNS transduction, coupled with the ability of genetically
corrected cells to secrete enzyme to cross-correct untransduced cells, would make this a
highly effective approach for the long-term treatment of CNS manifestations of MPS I.
In the present study, we tested the capacity of intrathecal delivery of an AAV9
vector to correct storage lesions throughout the CNS in a large animal model of MPS I.
We selected the feline MPS I model for these experiments because the CNS lesions in
these animals closely resemble those of MPS I patients, with accumulation of
gangliosides in neurons and GAGs in the meninges and around cerebral blood
vessels(Vite et al. 2011). We found that intrathecal delivery of a vector bearing the
normal feline IDUA sequence resulted in global CNS correction of the histological and
biochemical features of MPS I. IDUA-specific antibody responses were elicited in the
CNS of most treated animals, but were not associated with adverse clinical sequelae or
loss of efficacy. Together these results strongly support the development of intrathecal
AAV9-mediated gene delivery as a therapeutic approach for MPS I.
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Materials and Methods
Vector production: The feline IDUA sequence was isolated as described (Wang et al.,
manuscript in preparation). A codon-optimized version of the cDNA was cloned into
expression constructs flanked by AAV2 terminal repeats that contained the CMV or CB
promoter, a chimeric intron, and an SV40 or rabbit globin polyadenylation sequence.
The constructs were packaged in an AAV9 capsid by triple transfection of 293 cells and
purified as previously described (Wang et al. 2011).
Animal procedures:

The MPS I cat colony was maintained at the University of

Pennsylvania School of Veterinary Medicine under NIH and USDA guidelines for the
care and use of animals in research. All protocols were approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania. Approximately 3 mL
of blood was collected from the jugular vein for serum analysis. For intrathecal injections,
propofol-anesthetized animals were intubated, and the suboccipital region was clipped of
hair and scrubbed. Using sterile technique, a suboccipital puncture was performed with a
22 gauge spinal needle. Placement was confirmed by CSF return. After collecting 1 -2
mL of CSF, vector diluted in sterile PBS (1-2 mL) was slowly injected by hand. The
animals were monitored to confirm complete recovery after the procedure. Euthanasia
was by an intravenous overdose of sodium barbiturate, 80 mg/kg.
Enzyme assays: Tissue, serum, and CSF samples were immediately frozen on dry ice
and stored at -80 degrees until analysis. Serum and CSF were used directly in IDUA
and Hexosaminidase (Hex) assays. Tissue samples were homogenized in lysis buffer
(0.2 % Triton-X100, 0.9% NaCl, pH 4.0), and briefly sonicated. Samples were then
freeze-thawed and clarified by centrifugation. Protein concentrations were determined
by Bradford assay. IDUA activity was measured by incubating sample diluted in 0.1 mL
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water with 0.1 mL of 100 mM 4MU-iduronide (Toronto Research Chemicals; Glycosynth)
in IDUA buffer (0.15 M NaCl, 0.05% Triton-X100, 0.1 M sodium acetate, pH 3.58) at 37
degrees for 1-3 hours. The reaction was stopped by addition of 2 mL 290 mM glycine,
180 mM sodium citrate, pH 10.9.

The liberated 4MU was quantified by comparing

fluorescence to standard dilutions of 4MU. Units are given as nmol 4MU liberated per
hour per mg of protein (tissues) or per mL of serum or CSF.

Hex assays were

performed as described(Wendeler and Sandhoff 2009).
HCII-thrombin western blot: 0.5 µL of serum in 1x LDS buffer was separated on a 4-12%
Bis-Tris polyacrylamide gel (Novex) in MOPS buffer at 120 V for 2 hours. Protein was
transferred to a PVDF membrane at 30 V for 1.5 hours. The membrane was blocked for
1 hour in 5% NFDM, and then incubated overnight at 4 degrees in 5% NFDM containing
a 1:25,000 dilution of HRP-conjugated goat anti-HCII antibody (Enzyme Research). The
blot was washed and developed with a chemiluminescent substrate (Thermo Scientific).
GAG assay: Tissue samples were processed as for enzyme assays. Tissue GAGs
were quantified using the Blyscan assay (Biocolor, Carrickfergus, UK) according to the
manufacturer’s instructions.
ELISA for detection of antibodies to feline IDUA: A C-terminal his-tag was added to the
feline IDUA cDNA by PCR. The tagged cDNA was cloned into an expression cassette
driven by a CB promoter. This plasmid was transfected into six 90% confluent 10 cm
plates of HEK 293 cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Supernatant was collected twice at 24-hour intervals; each time the supernatant pH was
immediately titrated to pH 5.8, which vastly increased enzyme stability, and stored at 4
degrees. The enzyme was purified on a 1 mL HisTrap FF column (GE). The eluted
fractions were immediately adjusted to pH 5.8. The fractions containing purified feline
IDUA were identified by enzyme assay and SDS-PAGE.
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The purified protein was

incubated at 3 µg/mL in PBS, pH 5.8 on polystyrene ELISA plates overnight at 4
degrees. The plates were washed twice in PBS, pH 5.8, blocked in 3% BSA, pH 5.8,
and then incubated with diluted samples for one hour at room temperature. The plates
were washed 5 times, incubated 1 hour with a 1:10,000 dilution of HRP-conjugated goat
anti-feline IgG (Peirce, Rockford, IL) in blocking solution, washed 5 times, and
developed using TMB substrate.
Quantitative PCR: Quantification of vector genomes in tissue was performed as
previously described (Wang et al. 2011).
Histology: Brains were divided into left and right hemisphere. The right half was sliced
and, except for the distal occipital part, fixed in paraformaldehyde to be further
processed for GM3 and cholesterol detection. Slices from the left half were used for all
other stains as well as for PCR analysis and enzyme assays. For PCR and enzyme
analysis samples were collected from the frontal, temporal and occipital cortices as well
as medulla, hippocampus and cerebellum. Hippocampus samples included the entire
dissected hippocampus, spanning from CA1 to the DG.
Hematoxylin and eosin staining (H&E): H&E staining was performed on 6 µm sections
from formalin-fixed paraffin-embedded tissues according to standard protocols.
GM3

immunohistochemistry:

Brain

slices

were

fixed

overnight

in

4%

paraformaldehyde/PBS, equilibrated sequentially in 15% and 30% sucrose, and frozen
in OCT embedding medium.
Immunostaining was performed on 30 µm thick floating cryosections as described
(McGlynn, Dobrenis, and Walkley 2004) using monoclonal antibody DH2 (Glycotech,
Gaithersburg, MD) as primary antibody followed by a biotinylated secondary anti-mouse
antibody (Jackson Immunoresearch, West Grove, PA) and detection with a Vectastain
Elite ABC kit (Vector Labs, Burlingame, CA). Stained sections were transferred onto
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glass slides and mounted with Fluoromount G (Electron Microscopy Sciences, Hatfield,
PA).
GAG histochemistry: Brain samples were fixed overnight in methacarn (60% methanol,
30% chloroform, 10% glacial acetic acid) at 4ºC, dehydrated through an ethanol series
and xylene, and paraffin embedded. Deparaffinized 6 µm sections were stained in 1%
Alcian Blue (Sigma)/0.1 N HCl (pH1.0) for 15 min, rinsed in water for 2-3 min, and
counterstained with Nuclear Fast Red (Vector Labs).
Filipin stain: Cholesterol was detected on 30 µm thick cryosections prepared as
described for GM3 immunohistochemistry. Floating sections were stained with filipin
(Sigma, St Louis, MO, 10 µg/ml prepared from 3 mg/ml stock solution) for 1.5 h. After
washing in PBS (2 x 5 min), sections were mounted with Fluoromount G.
Immunofluorescence: Immunostaining was performed on 6 µm sections from formalinfixed paraffin-embedded tissue samples. Sections were deparaffinized through an
ethanol and xylene series, boiled in a microwave for 6 min in 10mM citrate buffer (pH
6.0) for antigen retrieval, and blocked with 1% donkey serum in PBS + 0.2% Triton for 15
min followed by sequential incubation with primary (1 h) and labeled secondary (45 min)
antibodies diluted in blocking buffer. Primary antibodies used were rabbit antibodies
against GFAP (Abcam, Cambridge, UK, 1:1000) and LIMP2 (Novus Biologicals, Littleton,
CO, 1:200), and FITC- or TRITC-labeled donkey anti-rabbit (Jackson Immunoresearch)
served as secondary antibody.
Morphometric analyses: Images taken for quantification purposes were acquired using
either a 4x (GM3), 10x (filipin), or 20x objective (GFAP,LIMP2, H&E) depending on the
lowest magnification that still allowed accurate visualization of neurons or astrocytes.
Images for GFAP and LIMP2 were taken from the area directly below the cerebral cortex
surface and include the cerebral molecular layer; all other images were centered on the
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middle to upper neuron layers of the cortex. The images shown for LIMP2, filipin and
H&E stained sections correspond to the region depicted in the second column of Figure
4. Five images from each brain were taken for analyzing storage in H&E sections as
well as GM3 and filipin staining which showed low variation between different brain
parts, while a total of 20 images (10 each from two different sections) were acquired for
GFAP and LIMP2 analyses. For quantification of GM3 and filipin positive neurons,
ImageJ

software

(Rasband

W.

S.,

National

Institutes

of

Health,

USA;

http://rsb.info.nih.gov/ij/) was used to first threshold images, i.e. to mark positively
stained cells, and then to count the number of these cells with the “Analyze Particles”
tool of ImageJ. GFAP and LIMP2 positive cells as well as storage-positive H&E-stained
neurons were counted manually.

Results
Intrathecal AAV9 delivery induced robust IDUA expression in CSF and serum
Eight MPS I cats between four and seven months of age were included in this
study (Table 3-1). These animals carried a three base pair deletion in the IDUA gene,
resulting in omission of a single aspartate residue (He et al. 1999).

Three cats

heterozygous for the IDUA mutation and two wild type animals from the same colony
served as unaffected controls. Five of the affected animals at ages 4 to 7 months were
treated with a single intrathecal injection via the cisterna magna of 1012 GC/kg of an
AAV9 vector bearing a codon-optimized normal feline IDUA sequence.

The vector

administered to two of the cats carried a chicken beta actin (CB) promoter; the other
three treated animals received a vector carrying a cytomegalovirus (CMV) promoter.
One additional animal assigned to receive the CB vector died under anesthesia during
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the pre-treatment CSF collection. There were no other adverse events throughout the
study period.
Serum and CSF were serially collected from the treated and naïve animals and
assayed for IDUA enzyme activity (Fig. 3-1). IDUA activity was not detected in samples
from untreated MPS I cats. Treated animals exhibited a rapid elevation in both CSF and
serum IDUA activity following vector injection, with peak activity exceeding that
measured in normal cats. The CB promoter appeared to be more active, inducing higher
enzyme levels in both CSF and serum. Following a peak at 21 days post injection, CSF
enzyme levels rapidly declined to near baseline in two animals, although activity
remained detectable at most time points. CSF IDUA activity stabilized at approximately
normal levels in the other three cats. Serum activity varied between the normal range
and baseline values, although high background in the serum assay precluded accurate
assessment of low levels of circulating enzyme.
Heterogeneous antibody responses were elicited against the therapeutic enzyme
The sharp decline in IDUA activity in some of the treated animals did not appear
to be consistent with a cellular immune response against the transduced cells, as
residual expression was detectable and there were no clinical signs of meningitis or
encephalitis.

CSF analysis revealed normal nucleated cell counts and only mildly

elevated protein, which was also observed in untreated MPS I cats (Table 3-2). We
suspected that this decline in CSF enzyme could be due to the induction of antibodies
against IDUA.

Indirect ELISA using purified feline IDUA as a target for capture of

antibodies showed clear antibody responses in the CSF of some of the treated animals
(Fig. 3-2a).

Within the CMV vector treated group, CSF IDUA activity decreased in
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proportion to antibody titer, with animal 8982 having the highest titer corresponding to
nearly undetectable CSF enzyme levels. The same was true for the animals treated with
the CB vector; animal 9050 exhibited elevated antibody titers and very low CSF IDUA
activity whereas 9058 maintained normal CSF IDUA and did not have a detectable
antibody response. The correlation was not as clear between the groups treated with
the different vectors, as the CB vector-treated animals appeared to have lower steady
state CSF antibody titers overall. Considering that these animals also had higher initial
enzyme expression, it is likely that the additional antigen either sequestered antibody or
interfered with ELISA-based detection, resulting in lower overall titer measurements in
this group. In summary there was a correlation between CSF IDUA antibody and steady
state level of CSF IDUA for all animals except 8911, which developed moderate levels of
CSF antibodies but retained high levels of steady state CSF enzyme.
Normalization of CSF hexosaminidase (Hex) activity despite antibody induction to the
therapeutic enzyme
IDUA deficiency has been shown to induce secondary elevation of activity of
other lysosomal glycohydrolases. We found that elevated activity of one such enzyme,
beta hexosamindase, was detectable in the CSF of MPS I cats (Fig. 3-2b).

This

elevated Hex activity in CSF provided a potential non-invasive biomarker to detect
aberrant cellular regulation in the CNS of MPS I cats. Following vector delivery, we
observed an approximately 2-fold decrease in CSF Hex activity in all treated animals.
Animals receiving the CB vector, which induced higher initial expression, exhibited the
most rapid normalization of CSF Hex. Only one animal (8982), which had high antiIDUA titers and very low CSF IDUA activity, exhibited incomplete normalization of CSF
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Hex. This demonstrated that all treated animals, even those that lost nearly all CSF
enzyme activity, exhibited a persistent biochemical response to gene transfer.
Intrathecal AAV9 delivery resulted in global CNS transduction and normalization of
tissue Hex activity
All treated animals were euthanized between 160 and 170 days following vector
delivery. We performed quantitative PCR analysis on DNA from tissue samples, which
revealed substantial vector deposition throughout the brain and spinal cord (Fig. 3-3a).
There were no differences in copy number in samples from animals with very low CSF
IDUA levels, further confirming that elimination of transduced cells played no role in the
decrease in circulating activity. Vector bio-distribution to peripheral organs was limited,
except to the liver, which contained very high vector copy numbers. All subsequent
analyses of transduction activity and biochemical and pathological correction are
presented in subgroups of cats with high (8911, 8932 and 9058) or low (8982 and 9050)
CSF IDUA.
IDUA activity was measured in tissue samples collected from various regions of
the brain and spinal cord (Fig. 3-3b). Activity was undetectable in untreated MPS I cats.
All treated animals exhibited elevated tissue IDUA activity, exceeding that of
heterozygous control animals in several brain regions. Tissue IDUA was lower in many
regions of the CNS in the animals with the lowest CSF enzyme activity, although in all
cases it was greater than that found in untreated MPS I cats. To evaluate tissue
correction of the MPS I phenotype in the CNS, Hex activity was measured in CNS tissue
lysates (Fig. 3-3c).

Similar to observations in the CSF, untreated animals had

significantly elevated tissue Hex activity, which was normalized in all brain regions of
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treated animals, including sites with very low IDUA activity. This indicates an extremely
low threshold for the expressed enzyme to effect changes in the abnormal cellular
processes associated with MPS I in the CNS. We also attempted to quantify total GAG
concentrations in the brain, but we found that the dimethylmethylene blue assay used for
these measurements exhibited high background in brain tissue and thus could not
reliably distinguish between normal and MPS I cats.
IDUA reconstitution reverses lysosomal storage lesions throughout the CNS
The CNS manifestations of MPS I are characterized histologically by intracellular
accumulation of cholesterol and the gangliosides GM2 and GM3 in the brain
parenchyma, with storage of GAGs prominent in the meninges and surrounding the
cerebral vasculature (Vite et al. 2011, McGlynn, Dobrenis, and Walkley 2004).
Untreated MPS I cats exhibited marked GM3 staining throughout multiple brain sections,
which was absent in normal controls (Fig. 3-4, Table 3-3). In treated animals, GM3
storage was cleared throughout all brain regions analyzed, although scattered cells
showing residual GM3 staining were visible in the animals with the lowest CSF enzyme
activity. The reduction in GM3 staining correlated with a reduced frequency of abnormal
neurons exhibiting distended cytoplasm visible on histopathology; while these were
frequently observed in the cortex of untreated cats, they were absent in treated animals
with high CSF IDUA activity, and rare in treated animals with lower CSF enzyme (Fig. 35, Table 3-3). Filipin staining for cholesterol revealed a similar pattern of correction, with
an average of 239 +/- 60 positive cells per field in untreated animals, which was reduced
to an average of 2 positive cells per field in animals with high CSF IDUA activity and 38
and 52 cells per field in treated animals with low CSF IDUA activity (Fig. 3-5, Table 3-3).
We also stained for LIMP2, a lysosomal integral membrane protein, which has been
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shown to accumulate in neurons in murine models of MPS (Haurigot et al. 2013). This
marker also showed considerable lysosomal storage in the brains of MPS I cats that was
almost completely normalized following intrathecal vector administration in all treated
animals (Fig. 3-5, Table 3-3).
To evaluate correction of storage pathology in the meninges and perivascular
spaces, Alcian blue staining for GAGs was performed on cortical tissue sections (Fig. 36). The untreated animals exhibited significant GAG accumulation in the thickened
meninges, as well as in perivascular cells. This GAG storage was almost completely
reversed in all treated animals.
Intrathecal AAV9 delivery corrects somatic lesions
It has previously been reported that AAV9 delivery into the CSF in a murine MPS
model results in both CNS and peripheral organ transduction, with corresponding
correction of peripheral pathology (Haurigot et al. 2013, Gray et al. 2013). It has also
been demonstrated that this distribution of vector to the periphery occurred after
intrathecal administration in primates and dogs, an observation confirmed by our PCR
analysis in the present study

29,

(Gray et al. 2013). Given the distribution of vector to the

periphery and significant serum IDUA activity, we evaluated somatic tissues for evidence
of disease correction.

Quantitative analysis of GAGs in liver and spleen showed

normalization in the liver of all treated animals, whereas splenic GAG storage was
corrected in animals which exhibited the lowest antibody titers in their treatment groups
(8911, 8932, 9058) but not in those that had the highest antibody titers within their
treatment group and had reduced CSF enzyme activity (Fig. 3-8). This is consistent with
IDUA being expressed primarily from the heavily transduced liver, with cross correction
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of distant organs such as the spleen occurring only in the absence of an interfering
antibody response.

Histological evaluation of GAG storage by Alcian blue stain

confirmed correction in the liver and spleen, as well as improvement in the heart and
lungs, which was more pronounced in the animals with lower antibody titers (Fig. 3-7).
The kidney appeared to have significant GAG storage that did not respond as readily to
treatment.
Serum levels of the covalent complex formed by thrombin and the protease
inhibitor heparin cofactor II (HCII) have been proposed as a biomarker in MPS I, as
formation of this complex is catalyzed by GAGs such as dermatan sulfate (LangfordSmith et al. 2011, Randall et al. 2008). We saw reductions in serum HCII-thrombin in all
treated animals, consistent with reduction in peripheral GAGs (Fig. 3-9). The response
appeared less robust in the two animals with high residual spleen GAGs.
Intrathecal AAV9 does not induce an inflammatory response in the CNS
One report has suggested that intrathecal AAV9 delivery can result in a robust
inflammatory response and cellular infiltration (Samaranch, San Sebastian, et al. 2013).
We evaluated hematoxylin and eosin stained tissue sections from cerebrum and
cerebellum for evidence of cellular infiltrates (Fig. 3-10). We also immunostained tissue
sections for GFAP, an astrocyte intermediate filament protein that is highly upregulated
in the context of inflammation (Fig. 3-11, Table 3-3). We observed no evidence of
cellular infiltration or astrocyte activation in any of the treated animals based on standard
histopathology or GFAP staining.
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Discussion
The goal of this study was to evaluate the feasibility of intrathecal gene therapy
for treating CNS manifestations of MPS I in an authentic large animal model as a
necessary step toward human trials. A previously described feline model of MPS I was
further characterized for biochemical and histological abnormalities as a prelude to an
evaluation of gene transfer.

Our study demonstrated diffuse CNS pathology in this

model, including neuronal storage lesions staining strongly for gangliosides and
cholesterol as well as pronounced meningeal and perivascular GAG storage, consistent
with previous reports (Vite et al. 2011). We also found accumulation of the lysomomal
membrane protein LIMP2 and elevation of hexosaminidase activity in the brains of MPS
I cats, as has been observed in other species (Haurigot et al. 2013). We found that a
single intrathecal administration of AAV9 expressing normal feline IDUA resulted in
virtually complete correction of the histological and biochemical features of MPS I in the
CNS. We could not directly assess the clinical consequences of treatment because
MPS I cats do not have a well-defined neurological phenotype, although mouse studies
suggest that correction of CNS storage pathology correlates with normalization of
cognitive deficits(Wolf et al. 2011).
Intrathecal AAV9 delivery could potentially be applied to many lysosomal storage
diseases affecting the CNS. However, MPS I may represent a particularly tractable
target due to the extremely low levels of enzyme required to correct lysosomal storage.
In vitro studies have shown that IDUA concentrations below 1 pM can reduce GAG
accumulation in MPS I patient fibroblasts, which would predict extremely efficient cross
correction of untransduced cells by enzyme secreted from even a small number of
genetically modified cells (Kakkis et al. 1994). MPS I is also an important target due to
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the substantial CNS morbidity in this disease and the limited efficacy and availability of
treatment options. BMT is currently the only therapeutic option with the potential to
modify the course of cognitive decline in patients with a severe phenotype, but this
comes with high morbidity and mortality.

Other CNS manifestations such as

communicating hydrocephalus and spinal cord compression also cause debilitating
symptoms and necessitate surgical interventions such as ventriculoperitoneal shunting
or spinal laminectomy (Kachur and Del Maestro 2000, Vijay and Wraith 2005, Taccone
et al. 1993, Ahmed et al. 2014, Furukawa et al. 2011, Zafeiriou and Batzios 2013). Our
results demonstrate that intrathecal AAV9 administration can reverse storage lesions in
both the brain parenchyma and the surrounding meninges, indicating the potential to
benefit patients with a variety of CNS sequelae of MPS I. In addition to the unmet
clinical need in MPS I and strong preclinical data, this disease presents some practical
benefits as a target for human trials. The ability to measure enzyme activity in the CSF
would allow for direct confirmation of transgene expression, and a variety of potential
biomarkers could be useful for assessing biological activity. In this study we found that
CSF hexosaminidase activity was elevated in MPS I animals and was normalized in
proportion to histological CNS correction, making this a strong candidate for a biomarker
in human trials. Longitudinal evaluation of the MRI findings typical of MPS I— enhanced
white matter signal intensity, enlarged perivascular spaces and meningeal thickening—
could also provide useful correlates of therapeutic activity (Zafeiriou and Batzios 2013).
We found that a variable antibody response against normal feline IDUA was
elicited by intrathecal AAV9-mediated expression. This might be expected, given that
nearly all MPS I patients develop antibodies against the enzyme during the course of
ERT. The heterogeneity of clinical responses and high prevalence of antibodies make it
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difficult to discern a clear effect of antibodies on therapeutic outcomes in humans, but
studies in MPS I dogs indicate that tissue correction from systemic ERT is significantly
reduced by high antibody titers (Dickson, Peinovich, et al. 2008). A study examining the
effect of antibody titer on the efficacy of intrathecal ERT in canine MPS I likewise
showed that antibodies reduce treatment efficacy in the CNS (Dickson et al. 2012). Our
results suggest that while anti-IDUA antibodies impact the efficiency of tissue correction,
cross correction of untransduced cells remains reasonably effective in the setting of an
antibody response. Some degree of residual efficacy after antibody induction against
IDUA could also be explained by intracellular enzyme production alone; however, a
previous study demonstrated that intracisternal AAV9 delivery at the dose tested
transduces only a small fraction of cells in the feline brain, suggesting that widespread
reversal of storage lesions is due to cross-correction. Most critically, development of an
antibody response against IDUA in the CSF was not associated with adverse clinical
events or histological evidence of inflammation. Together these data strongly support
the safety and efficacy of this approach, even with the risk of developing antibodies
against the therapeutic enzyme. Given the correlation we observed between antibody
titer and histological evidence of efficacy, measuring CSF antibody titers may be
informative for predicting clinical outcomes in human trials.

Long-term follow up of

patients treated with systemic ERT has shown that antibody titers fall to baseline levels
in most patients within two years of treatment initiation, suggesting that a similar decline
in titer may be seen in the context of gene therapy, which would further support the
potential for robust long-term clinical benefit(Kakavanos et al. 2003).

Long-term

evaluation of AAV9 intrathecal gene therapy in feline MPS I is currently underway.
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Here, we have demonstrated proof-of-principle that intrathecal AAV9 delivery can
globally correct CNS manifestations of MPS I in a high-fidelity large animal model, even
when antibodies are elicited against the therapeutic enzyme. The excellent tolerability
and efficacy of this approach support progression into human trials for MPS I. These
promising results also suggest that this approach may serve as a broad platform for the
treatment of other lysosomal storage diseases affecting the CNS.

Figure 3-1. IDUA expression in CSF and serum following IT AAV9 delivery
Five MPS I cats were treated with an intracisternal injection of an AAV9 vector (10

12

GC/kg) expressing feline IDUA from a CB (gray symbols) or CMV (black symbols)
promoter. CSF and serum were serially collected from the treated animals as well as
three untreated MPS I cats. IDUA activity was measured using the fluorogenic substrate
4MU-iduronide in CSF (a) and serum (b). All values are the mean of duplicate assays.
Normal serum and CSF activity (dashed line) are the mean values from two wild type
animals.
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Figure 3-2. Normalization of CSF hexosaminidase activity despite a transgene-specific
antibody response
CSF samples collected before vector administration and at the end of the study were
tested for the presence of antibodies against IDUA by indirect ELISA (a). Titers are
based on a standard curve of a serially diluted positive sample, which was arbitrarily
assigned a titer of 1:1000.

(b) Total Hex activity was measured in CSF using the

fluorogenic substrate MUG. Normal activity (dashed line) is the mean of two
heterozygous control samples. The untreated MPS I level (dotted line) is the mean of
untreated controls.
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Figure 3-3. Global CNS transduction and biochemical correction following IT gene
transfer
Vector genomes were quantified in DNA extracted from CNS and peripheral tissues of
treated cats by TaqMan PCR (a). Tissue samples from MPS I cats and heterozygous
controls were collected from sites throughout the CNS for measurement of IDUA activity
(b) and Hex activity (c). Treated animals are stratified into those with normal CSF IDUA
activity (8911, 8932, 9058) and those with low CSF activity (8982, 9050). All enzyme
activities are normalized to protein concentration.
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Figure 3-4. Reversal of brain ganglioside storage
Immunostaining for the ganglioside GM3 was performed on tissue sections from four
brain regions in untreated MPS I cats (a-d), treated cats with high CSF IDUA activity (EH) and low CSF activity (i-l), as well as normal controls (m-p). Scale bar = 500 µM.
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Figure 3-5. Correction of neuronal storage lesions
Sections from the cerebral cortex were stained with H&E (a, f, k, p). Arrows indicate the
distended neuron cell bodies typical of MPS I. The treated cats were stratified into those
with low CSF IDUA activity and those with high activity. Cholesterol accumulation was
evaluated in matched brain sections by filipin staining in untreated (b,c), treated (g, h, l,
m) and normal control (q, r) cats. Immunostaining for the lysosomal integral membrane
protein LIMP2 was performed on corresponding sections from each animal (d, e, i, j, n,
o, s, t). Scale bar = 500 µM (4x), 200 µM (10x) or 100 µM (H&E).
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Figure 3-6. Reduced GAG storage in the cerebral vasculature and meninges
Cortical brain sections were stained for GAGs using alcian blue. Low magnification
images (a,d, g, j) show the cerebral cortex with the associated meninges. High
magnification images show representative cortical blood vessels (b, e, h, k) and
segments of meninges (c, f, i, l). Scale bars = 500 µM (left column) and 100 µM (middle
and right columns).
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Figure 3-7. Correction of somatic lesions
Sections from heart, lung, liver, spleen and kidney were stained with Alcian blue.
Animals are stratified according to antibody response and circulating enzyme activity as
in Figure 6. Scale bar = 100 µM.
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Figure 3-8. Peripheral GAG clearance following intrathecal AAV9 delivery
GAG content of liver and spleen lysates was measured by dimethylmethylene blue
binding assay. Animals are stratified into those that had the highest antibody titers and
the lowest circulating CSF enzyme in their treatment group (9050, 8982) and those that
exhibited more stable expression (8911, 8932, 9058). Values are normalized to sample
protein concentration.
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Figure 3-9. Reduced serum heparin cofactor II-thrombin complex concentration
following intrathecal gene therapy
Serum concentrations of the heparin cofactor II-thrombin complex were assessed by
western blot, using a polyclonal anti-human HCII antibody for detection. Lane 1-3:
heterozygous controls, lane 4-6: untreated controls, lane 7: 8911, lane 8: 8932, lane 9:
8982, lane 10: 9050, lane 11: 9058.
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Figure 3-10. Absence of inflammation or cellular infiltration in treated animals

Tissue sections from cerebrum (A-H) and cerebellum (I-P) were stained with H&E.
Images depict representative segments of meninges and blood vessels. Scale bar = 50
µM.
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Figure 3-11. Absence of astrocyte activation in treated animals

Tissue sections from cerebral cortex were stained with an anti-GFAP antibody. Scale
bars = 500 µM (low magnification) and 100 µM (high magnification).
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Table 3-1. Summary of study subjects

Animal
#
9110
9115
7704
8991
8992
8922
9052
9055
8911

8932

8982

Genotype

Treatment

Dose

Weight
injection

WT

Untreated

-

WT

Untreated

MPS I Het

at

Sex

Age at study
end

-

M

7 months

-

-

F

7 months

Untreated

-

-

F

58 months

MPS I Het

Untreated

-

-

F

6 months

MPS I Het

Untreated

-

-

F

6 months

MPS I

Untreated

-

-

F

13 months

MPS I

Untreated

-

-

F

10 months

MPS I

Untreated

-

-

M

10 months

MPS I

AAV9-CMVfIDUA

10
GC/kg

2.43 kg

F

13 months

MPS I

AAV9-CMVfIDUA

10
GC/kg

2.89 kg

M

12 months

MPS I

AAV9-CMVfIDUA

10
GC/kg

1.83 kg

F

10 months

MPS I

AAV9-CB-fIDUA

10
GC/kg

1.14 kg

F

10 months

MPS I

AAV9-CB-fIDUA

10
GC/kg

1.35 kg

F

10 months

12

12

12

12

9050

12

9058
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Table 3-2. CSF analysis in treated and control MPS I cats
Nucleated Cells/µlA

Total Protein (mg/dL)B

Animal
Treatment

Day 21

51

77

101-7

21

51

77

101-7

8911

AAV9.CMV.fIDUA

0

1

ND

2

<25

<25

ND

<25

8932

AAV9.CMV.fIDUA

1

0

ND

1

<25

26

ND

29

8982

AAV9.CMV.fIDUA

1

1

ND

1

<25

<25

ND

33

9050

AAV9.CB7.fIDUA

ND

1

1

1

ND

29

<25

26

9058

AAV9.CB7.fIDUA

ND

0

1

3

ND

30

29

25

8922

Untreated

0

1

ND

1

<25

<25

ND

27

9052

Untreated

ND

0

0

1

ND

<25

<25

<25

9055

Untreated

ND

0

1

1

ND

26

28

41

ID

A. Normal range ≤ 2 cells / µl
B. Normal range ≤ 25 mg/dL
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Table 3-3. Quantification of histopathology and GM3, LIMP2, filipin and GFAP
positive cells per field in matched brain sectionsA

Animal ID

Treatment

Genotype

GM3

H&EB

LIMP2

Filipin

GFAP

9110

Untreated

WT

2.6 ± 1.9

0.4 ± 0.5

0.2 ± 0.4

3.5 ± 2

17.7 ± 8.1

9115

Untreated

WT

8.4 ± 7.3

0.8 ± 0.8

0.2 ± 0.4

3.8 ± 2.4

11.1 ± 8.2

7704

Untreated

MPS I Het

0.2 ± 0.45

0.2 ± 0.4

13.4 ± 3.2

0±0

19.3 ± 7.4

8992

Untreated

MPS I Het

0.8 ± 0.84

0.2 ± 0.4

6.1 ± 3.8

0±0

20.7 ± 6.6

8991

Untreated

MPS I Het

7.2 ± 6.0

0.6 ± 0.9

14.1 ± 4.5

0±0

11.9 ± 2.9

8922

Untreated

MPS I

380.4 ±
88.8

9.4 ± 3.6

85.2 ± 6.2

274.6 ±
54.7

29.4 ±5.7

9052

Untreated

MPS I

239 ±
89.13

8.2 ± 2.4

75.8 ± 7.9

271.8 ±
82.9

28.8 ±
12.6

9055

Untreated

MPS I

272.2 ±
66.2

5.4 ± 4.7

80 ± 7.6

169.2 ±
23.4

25 ± 7.1

8911

AAV9.CM
V.fIDUA

MPS I

7.2 ± 3.83

0.6 ± 0.9

16.3 ± 5.5

5.2 ± 4.3

18.6 ± 6.8

8932

AAV9.CM
V.fIDUA

MPS I

8 ± 6.48

0.6 ± 0.5

11.4 ± 6.7

0.6 ± 1.3

23.3 ± 6.9

8982

AAV9.CM
V.fIDUA

MPS I

46.8 ±
10.75

1±1

34.7 ±
21.7

52 ± 12.4

25.1 ± 5.8

9050

AAV9.CB.f
IDUA

MPS I

24 ±
15.95

1.8 ± 0.8

9.2 ± 6.7

38 ± 26.5

16.4 ± 5.9

9058

AAV9.CB.f
IDUA

MPS I

14 ± 5.43

0.4 ± 0.5

2.6 ± 1.2

0±0

17.1 ± 7.1

A. Cells staining positive for the indicated marker were quantified in 5 fields (GM3, Filipin, H&E)
or 20 fields (LIMP2 and GFAP) from matched brain regions. Quantification is per 20x field for
GFAP, LIMP2, and H&E, 10x field for filipin, and 4x field for GM3.
B. Indicates number of cells exhibiting distended, asymmetric pale cytoplasm characteristic of
neuronal storage
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CHAPTER 4: Neonatal systemic AAV induces tolerance to CNS
gene therapy in MPS I dogs and nonhuman primates

Chapter 4 is adapted from: C. Hinderer, P. Bell, J. P. Louboutin, Y. Zhu, H. Yu, G. Lin, R.
Choa, B. L. Gurda, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P. Wang, A. F. Tarantal,
M. L. Casal, M. E. Haskins, J. M. Wilson. Molecular therapy (2015).
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Abstract
The potential host immune response to a non-self protein poses a fundamental
challenge for gene therapies targeting recessive diseases. We demonstrate in both dogs
and nonhuman primates that liver directed gene transfer using an adeno-associated
virus (AAV) vector in neonates induces a persistent state of immunological tolerance to
the transgene, substantially improving the efficacy of subsequent vector administration
targeting the central nervous system (CNS). We applied this approach to a canine model
of mucopolysaccharidosis type I (MPS I), a progressive neuropathic lysosomal storage
disease caused by deficient activity of the enzyme α-l-iduronidase (IDUA). MPS I dogs
treated systemically in the first week of life with a vector expressing canine IDUA did not
develop antibodies against the enzyme and exhibited robust expression in the CNS
upon intrathecal AAV delivery at one month of age, resulting in complete correction of
brain storage lesions. Newborn rhesus monkeys treated systemically with AAV vector
expressing human IDUA developed tolerance to the transgene, resulting in high CSF
IDUA expression and no antibody induction after subsequent CNS gene therapy. These
findings suggest that inducing tolerance to the transgene during a critical period in
immunological development will improve the efficacy and safety of gene therapy.

Introduction
The lysosomal storage diseases (LSDs) are a broad class of inherited disorders
caused by deficient activity of enzymes involved in the lysosomal catabolism of
ubiquitous

polysaccharides,

glycoproteins,

and

lipids,

leading

to

intracellular

accumulation of these undegraded enzyme substrates and multi-organ pathology. LSDs
are excellent targets for gene therapy because many of the associated lysosomal
enzymes can be secreted by genetically corrected cells and endocytosed by neighboring
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cells, allowing for widespread cross-correction even with modest gene transfer efficiency
(Dahms, Lobel, and Kornfeld 1989, Sando and Neufeld 1977). Gene therapy may play a
particularly important role in treating the central nervous system (CNS) manifestations
associated with LSDs, because the CNS cannot be effectively targeted by intravenous
(IV) delivery of the deficient enzymes, and chronic direct CNS administration is
impractical as a long-term therapy. One LSD in which gene therapy has shown particular
promise for treating CNS disease is mucopolysaccharidosis type I (MPS I), which is
caused by deficient activity of the lysosomal enzyme α-l-iduronidase (IDUA). Currently,
the only treatment capable of curbing the severe cognitive decline experienced by many
MPS I patients is hematopoietic stem cell transplantation, which is associated with
substantial morbidity and mortality (Aldenboven, Boelens, and de Koning 2008, Boelens
et al. 2007, Clarke et al. 2009, Langford-Smith et al. 2011, Sifuentes et al. 2007, Souillet
et al. 2003, Whitley et al. 1993). Using a naturally occurring cat model of MPS I, we
found that a minimally invasive intrathecal injection of an AAV serotype 9 vector into the
cerebrospinal fluid (CSF) achieved widespread gene transfer in the brain and sufficient
secretion of the therapeutic enzyme into the CSF to correct storage pathology
throughout the CNS (Hinderer, Bell, et al. 2014a). Intrathecal AAV delivery could,
therefore, represent a vast improvement over the current standard of care for CNS
disease in MPS I patients.
Despite the promise of intrathecal AAV delivery for MPS I, we found that the
efficacy of gene transfer was diminished in some MPS I cats due to development of
antibodies to IDUA, resulting in reduced circulating enzyme in the CSF and less efficient
correction of storage lesions.

Here we report that MPS I dogs, another naturally

occurring disease model, also develop antibodies to the normal canine enzyme following
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intrathecal gene therapy leading to less efficient correction of brain lesions. These
findings reflect the clinical experience with enzyme replacement therapy in MPS I, as
patients treated with recombinant IDUA almost universally develop antibodies to the
enzyme, which correlate with a poor response to therapy (Wraith et al. 2007, Langereis
et al. 2014).
With the goal of developing a safe and effective method for the prevention of
anti-transgene immune responses, we explored the possibility of exploiting the normal
processes by which the immune system learns to distinguish self from non-self. Decades
of evidence from transplantation studies suggest that neonatal rodents and humans,
unlike adults, are prone to develop tolerance rather than immunity to alloantigens (Fan et
al. 2004, McCarthy and Bach 1983, Billingham, Brent, and Medawar 1953). While this
phenomenon has often been ascribed to an immature and poorly functional immune
system, it has since become clear that neonates are indeed capable of eliciting
functional immune responses, albeit with higher activation thresholds (Adkins 1999). The
development of tolerance to neoantigens in newborns is instead an active process
involving peripheral anergy and deletion of reactive T and B cells, as well as induction of
regulatory T cells (Fan et al. 2004, McCarthy and Bach 1983, Wang et al. 2010). One
recent report demonstrated that this phenomenon could be exploited to induce durable
tolerance to factor VIII in hemophilic mice by performing gene transfer in neonates (Hu
et al. 2011). While this effect in mice could be attributed to the relative immaturity of the
murine immune system at birth, evidence for neonatal tolerance to a foreign transgene
has also emerged in studies using retroviral vectors in newborn dogs (Traas et al. 2007,
Xu et al. 2007). These experiments demonstrated sustained expression of relatively
immunogenic transgenes after neonatal retroviral vector administration, although the
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ineffectiveness of these vectors in adults precluded direct comparison of immune
responses to the transgene in animals of different ages.
In this study, we evaluated the potential for neonatal AAV-mediated systemic
expression of a therapeutic protein to induce immunological tolerance that could
subsequently allow for safe and effective CNS directed gene therapy. We found that
MPS I dogs treated intravenously in the first week of life with an AAV vector expressing
canine IDUA from a liver specific promoter did not develop antibodies to the transgene,
and following subsequent intrathecal gene transfer at one month of age exhibited 3- to
100-fold higher IDUA levels in CSF than naïve dogs, with complete resolution of brain
storage lesions. Likewise, rhesus monkeys administered liver-directed human IDUA
gene transfer at birth exhibited tolerance to the protein, allowing for robust CSF IDUA
expression without antibody induction after intrathecal AAV injection one month later.
These findings suggest a potential approach to prevent immune responses to a non-self
transgene through neonatal gene transfer, which could significantly improve the efficacy
of gene therapy for many recessive diseases.

Materials and Methods
Vector production
The AAV8 vectors contained codon optimized canine or human IDUA cDNA downstream
of the thyroid hormone binding globulin promoter. The AAV9 vector contained the
chicken beta actin promoter with a cytomegalovirus immediate early enhancer. Both
vectors included the rabbit beta-globin polyadenylation sequence. Vectors were
produced by triple transfection of 293 cells and purified on iodixanol gradients as
previously described (Wang et al. 2011).
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MPS I dogs
The MPS I dog colony was maintained at the University Of Pennsylvania School Of
Veterinary Medicine under NIH and USDA guidelines for the care and use of animals in
research. All MPS I dog study protocols were approved by the University of
Pennsylvania Institutional Animal Care and Use Committee. For vector injections in
neonatal MPS I dogs, the AAV8 vector was diluted in 0.5-1 mL of sterile saline, and
injected via the jugular vein. Intrathecal injections of AAV9 vectors and CSF collection
were performed via the suboccipital approach as previously described (Hinderer, Bell, et
al. 2014a). A total of 9 MPS I dogs were included in this study. Genotype was confirmed
at birth by PCR and serum enzyme assay. Six dogs were administered an IV injection of
the AAV serotype 8 vector (5 x 1012 genome copies per kilogram [GC/kg] body weight)
on either the first (N=3) or seventh (N=3) day of life. One animal died on postnatal day 3.
The remaining 5 treated animals as well as 3 naïve MPS I dogs were treated with
intrathecal AAV9 (1012 GC/kg) at one month of age. Blood was collected from a
peripheral vessel weekly for the first seven weeks of life then monthly thereafter. CSF (1
mL) was collected at the time of intrathecal vector injection (one month of age), on days
7 and 21 after injection, and monthly thereafter. Euthanasia was performed by
administration of sodium pentobarbital (80 mg/kg IV). Five animals (I-549, I-550, I-552, I553, I-554) were euthanized at 9 months of age; 3 (I-562, I-563, I-564) were euthanized
at 11 months of age. Untreated MPS I and controls were euthanized between 6 and 26
months of age (Table 1). Tissues were collected and processed as previously described
(Hinderer, Bell, et al. 2014a).
Rhesus Monkeys
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All animal procedures conformed to the requirements of the Animal Welfare Act and
protocols were approved prior to implementation by the Institutional Animal Care and
Use Committee at the University of California, Davis. Activities related to animal care
were performed as per California National Primate Research Center standard operating
procedures. Normally cycling, adult female rhesus monkeys (Macaca mulatta; N=4) with
a history of prior pregnancy were bred and identified as pregnant, using established
methods (Tarantal 2005). All dams selected for the study were pre-screened to ensure
they were seronegative for AAV antibodies. Fetuses were monitored sonographically
during gestation to confirm normal growth and development (Tarantal 2005) and
newborns were delivered by cesarean section at term (160±2 days gestation) according
to established protocols (Tarantal et al. 2005). Newborns were placed in incubators postdelivery and nursery-reared for the study. Infant health, food intake, and body weights
were recorded daily or weekly (dependent on age) in the nursery according to
established protocols. At birth all animals were administered the selected AAV vector IV.
At one month postnatal age and at subsequent monthly time points (up to 2 months
post-transfer, to date) infants were sedated with ketamine (10 mg/kg intramuscularly, IM)
and dexmedetomidine (0.015-0.075 mg/kg IM) in preparation for collection of CSF (~0.5
ml; pre-injection then weekly or monthly) and for intrathecal injection via the suboccipital
approach (~ 0.5 ml volume; 1 month and immediately after collection of CSF), all under
aseptic conditions. Blood samples were collected at birth then monthly from a peripheral
vessel (~ 3-6 ml) to monitor CBCs and clinical chemistry panels, and for collection of
serum and plasma. The reversal atipamezole was given IM at a comparable dose to
dexmedetomidine when sample collection was completed.
Vector Biodistribution
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DNA was isolated from tissues and vector genomes quantified by TaqMan PCR as
described (Wang et al. 2011).
Enzyme activity assays
Assays for IDUA and Hex activity were performed as described (Hinderer, Bell, et al.
2014a).
CSF pGAG measurement
CSF pGAG measurement was performed by the Glycotechnology Core at the University
of California, San Diego using previously described methods (Lawrence et al. 2012).
Briefly, GAG was extracted from CSF samples and digested to disaccharides with
heparinase I, II, and III. Disaccharides were tagged with aniline 12C by reductive coupling
and dried by speed vac. Dried samples were reconstituted in LC-MS grade water and
spiked with a known concentration of

12

C-aniline tagged standard. Samples were

analyzed on a LTQ Orbitrap Discovery electrospray ionization mass spectrometer
(Thermo Scientific) equipped with Thermo Scientific Ultimate 3000 HPLC system.
ELISA
The ELISA for antibodies to canine IDUA was performed as described (Hinderer, Bell, et
al. 2014a), except that the expression construct contained the canine cDNA under the
control of the thyroid hormone binding globulin promoter, and the cIDUA protein was
produced in Huh7 cells. The detection antibody used was HRP-conjugated sheep anticanine (Pierce, Rockford, IL). The assay for antibodies to human IDUA in rhesus
monkeys was identical, except that Aldurazyme (Genzyme, Cambridge, MA) 10 µg/mL,
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was used for coating antigen and the detection antibody was polyclonal goat anti-human
(Jackson ImmunoResearch Laboratories, West Grove, PA).
Histology
Histological analysis of MPS I dog brains was performed as previously described
(Hinderer, Bell, et al. 2014a) with the following modifications for quantifying neurons
positive for GM3, cholesterol, and LIMP2 storage: Images of LIMP2- and filipin-stained
sections of cerebral cortex were taken with a 10x objective such that the border between
layer I (molecular layer) and layer II formed the upper border of the image. A total of 10
images were acquired from each animal. Images of GM3-stained brain sections were
taken with a 4x objective from the area directly below the cerebral cortex surface
including the cerebral molecular layer. Seven images from each animal were analyzed.
All images were processed with ImageJ software (Rasband W. S., National Institutes of
Health, USA; http://rsb.info.nih.gov/ij/) using the “Threshold” and “Analyze particles”
modules as described previously (3).

Results
Antibody Induction to Canine IDUA after Intrathecal AAV9-mediated Gene Transfer in
MPS I Dogs
The canine model of MPS I faithfully recapitulates many of the manifestations of
the human disease (Kakkis, McEntee, et al. 2004, Shull et al. 1984). These animals
have no detectable IDUA activity due to a splice site mutation that results in retention of
the first intron of IDUA (Menon, Tieu, and Neufeld 1992). Given the absence of
detectable IDUA expression in these animals, we anticipate that they will model the
immune response to intrathecal gene therapy that would occur in patients with the
84

severe form of MPS I, as these individuals generally carry alleles that produce no full
length IDUA, leaving them immunologically naïve to the protein (Terlato and Cox 2003).
The brains of MPS I dogs show the characteristic pathology associated with MPS I,
including widespread storage of gangliosides such as GM3 in neurons, as well as
abnormal accumulation of cholesterol and lysosomal membrane proteins including
LIMP2 (Shull et al. 1984). MPS I dogs also exhibit prominent storage of
glycosaminoglycans (GAGs) in the meninges, resulting in significant meningeal
thickening, a process which contributes to spinal cord compression in some MPS I
patients (Kachur and Del Maestro 2000, Taccone et al. 1993, Vijay and Wraith 2005).
We initially treated 3 dogs at one month of age with an intrathecal injection of an
AAV9 vector carrying the canine IDUA sequence under the control of a ubiquitous
promoter (Table 4-1). The injection was well tolerated in all animals; no clinical signs
were observed throughout the study. CSF analyses were generally unremarkable, with
only a mild transient elevation of CSF lymphocytes occurring in 2 animals (Table 4-2). A
single CSF sample in one animal showed a marked pleocytosis consisting primarily of
monocytoid cells. A subsequent tap showed no evidence of pleocytosis, and at the time
of euthanasia, there was no histological evidence of inflammation in the brain or spinal
cord of any treated animal.
The vector was distributed throughout the CNS, transducing cells in all analyzed
regions of the brain and spinal cord (Table 4-3). All animals exhibited supraphysiologic
expression of IDUA in CSF, which declined to the normal range in one animal (I-550)
and to below normal levels in two animals (I-553 and I-554), after which CSF enzyme
levels were essentially stable for 5 months until the animals were euthanized (Fig. 4-1a).
The absence of clinical signs, vector genome loss, or histological evidence of
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encephalitis indicated that the decline in CSF IDUA activity was not due to killing of
transduced cells by cytotoxic T lymphocytes, which was also supported by persistent
residual CSF IDUA activity. Instead, the decline in CSF IDUA activity was associated
with the induction of high titer antibodies against canine IDUA in CSF (Fig. 4-1b).
Induction of Tolerance to IDUA by Neonatal Gene Transfer
To determine whether neonatal expression of canine IDUA could induce immune
tolerance to the enzyme in MPS I dogs, we treated 6 animals with an IV injection of an
AAV serotype 8 vector expressing canine IDUA from a liver selective promoter on either
the first (N=3) or the seventh (N=3) day after birth (Table 4-1). One of the dogs treated
on postnatal day one died two days after treatment. Overall survival of neonates was
similar to historical data for untreated MPS I dogs, which have approximately 20%
mortality in the first two weeks of life (Traas et al. 2007). The cause of this early mortality
in MPS I dogs has not been determined; in this treated animal postmortem examination
showed systemic lesions typical of MPS I as well as possible evidence of a systemic
bacterial infection. Treated animals demonstrated an elevation in serum IDUA followed
by a rapid decline (Fig. 4-5). This is consistent with observations of transient expression
due to vector genome loss during hepatocyte division in previous studies utilizing nonintegrating vectors for hepatic gene transfer in newborns (Wang et al. 2012).
At one month of age, the five surviving dogs that received IV AAV8 in the first
week of life were given an injection of an AAV9 vector using an intrathecal approach. All
5 animals exhibited greater than 30-fold normal peak levels of IDUA in CSF following
intrathecal vector injection, with long term CSF enzyme levels 3- to 100-fold higher than
those achieved in naïve animals (Fig. 4-1a). Antibodies to canine IDUA in the CSF were
reduced nearly 100-fold compared to the animals treated with IT AAV9 alone, with
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undetectable CSF antibodies in the dogs treated on postnatal day 1, and low but
detectable responses in the animals treated on postnatal day 7 (Fig. 4-1b). All animals
treated as neonates exhibited no detectable serum antibodies against canine IDUA,
whereas the animals treated with IT AAV9 alone at one month of age had elevated
serum anti-cIDUA titers (Fig. 4-1c).
Induction of tolerance to canine IDUA in neonates is not due to hepatic expression
Previous studies in both mice and dogs have demonstrated tolerance induction
to foreign proteins through AAV-mediated hepatic expression(LoDuca, Hoffman, and
Herzog 2009, Crudele et al. 2015, Finn et al. 2010, Sun et al. 2010). To determine
whether immune tolerance in the animals treated with intravenous AAV8 as neonates
was due to liver targeted expression rather than the age of the animal at the time of
treatment, we treated 4 MPS I dogs at 3 months of age with an intravenous injection of
the AAV8 vector expressing canine IDUA from a liver specific promoter. All 4 animals
developed serum antibodies against the transgene product (Fig. 4-1c). This indicates
that the lack of antibody response to IDUA in the neonatal gene transfer cohort is related
to the age of the animal at the time of exposure to the transgene product, rather than the
presence of hepatic expression.
Correction of Biochemical and Histological Abnormalities in the CNS of MPS I Dogs
The lysosomal enzyme hexosaminidase (Hex) is upregulated in tissues of MPS I
animals, and the elevated Hex activity in both brain tissue and CSF serves as a useful
marker for the aberrant cellular processes occurring downstream of IDUA deficiency
(Hinderer, Bell, et al. 2014c). Measurement of CSF Hex activity at the time of intrathecal
vector delivery (~1 month postnatal) revealed abnormally elevated Hex activity in all
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MPS I dogs (Fig. 4-2a). The animals treated with intrathecal AAV9 alone exhibited
modest reductions in CSF Hex activity, with only the animal with the highest residual
IDUA expression (I-550) reaching the normal range. All 5 animals treated with neonatal
systemic gene transfer followed by intrathecal vector administration demonstrated
complete normalization of CSF Hex. Hex activity in brain tissue samples showed a
greater response to therapy than CSF Hex, with substantial reductions in brain Hex
activity in all treated animals, although the effect was slightly diminished in the two
intrathecal-only treated animals with the lowest CSF IDUA levels (Fig. 4-2b).
GAG concentrations in CSF were measured using an assay specific for the nonreducing end of the pathologic GAGs (pGAG) that accumulate due to IDUA deficiency
(Fig. 4-2c) (Lawrence et al. 2012). All animals exhibited a marked reduction in CSF
pGAG concentration 3 weeks after intrathecal AAV injection. This reduction was
sustained at day 112, although the dogs that were not immune tolerant to IDUA
maintained higher residual CSF pGAG than immune tolerant dogs.
Histological analysis revealed severe storage lesions throughout the brains of
untreated MPS I dogs, with widespread neuronal accumulation of GM3, cholesterol, and
LIMP2 (Fig. 4-3). The animals treated with intrathecal AAV9 alone demonstrated
substantial improvements in storage lesions, although only the animal with the highest
CSF IDUA (I-550) experienced complete resolution of neuronal storage. The other two
intrathecal-treated dogs had residual storage lesions. CNS storage lesions were
completely reversed in all 5 dogs treated with neonatal AAV8 systemic gene transfer
followed by intrathecal AAV9 administration.
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In addition to the storage lesions in the brain parenchyma, untreated MPS I dogs
showed accumulation of GAGs in meninges visible by Alcian blue stain (Fig. 4-3). This
meningeal GAG accumulation and the resulting thickening of the meninges is implicated
in many cases of spinal cord compression requiring surgical intervention, and also likely
contributes to the development of communicating hydrocephalus in some MPS I patients
by interfering with normal routes of CSF resorption. All treated animals showed evidence
of improvement in meningeal GAG storage. While the meninges appeared almost
completely normal in all tolerant dogs and one nontolerant dog, the two nontolerant
animals with the lowest CSF IDUA activity retained some meningeal GAG storage.
Induction of Tolerance to Human IDUA in Newborn Rhesus Macaques
To assess whether the neonatal window for immune tolerance induction that was
observed in MPS I dogs could also be found in primates, a similar study was performed
in newborn rhesus monkeys (N=4). Because these animals are not IDUA deficient, the
human IDUA transgene was used to model the immune response that might be
expected against a species-specific transgene in a patient lacking the endogenous
protein. Two newborn rhesus monkeys were administered AAV8 vector expressing
human IDUA from a liver specific promoter IV at birth. Both demonstrated a brief
increase in serum IDUA activity (Fig. 4-6). Two additional newborns were administered
an AAV8 vector expressing an irrelevant transgene (human factor IX) IV at birth. All four
animals were administered AAV9 vector expressing human IDUA at one-month
postnatal age by intrathecal injection. Similar to the MPS I dogs, the IDUA naïve animals
exhibited declining CSF IDUA activity 3 weeks after injection, with a return to near
baseline levels by 2 months post-administration (Fig. 4-4a). These animals also
developed transgene specific antibodies in the CSF (Fig. 4-4b). The two animals
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administered IDUA gene transfer IV at birth did not develop antibodies to human IDUA in
CSF (Fig. 4-4b), and maintained CSF enzyme activity greater than 10-fold normal (Fig.
4-4a) two months after intrathecal AAV9 administration. Unlike the kinetics of CSF IDUA
expression observed in dogs, CSF IDUA activity continued to increase 60 days after IT
vector administration, although overall expression was lower in NHP as previously
described(Nietupski et al. 2011). The animals developed neutralizing antibodies to the
vector capsids following both the IV administration at birth and the subsequent IT
injection (Table 4-2). All animals remained robust and healthy during the study period
with no evidence of adverse effects, normal growth trajectories, and complete blood
counts (CBCs) and chemistry panels within normal limits based on age and when
compared to historical controls.

Discussion
Immune activation to a wild type therapeutic protein is a potential obstacle to the
successful treatment of any recessive disease. Antibody responses to protein
replacement therapy have been particularly challenging for some LSDs, as antibodies
can interfere with the distribution and uptake of the intravenously delivered enzyme
(Langereis et al. 2014). Antibodies may be equally problematic for gene therapies
targeting these disorders, as they can interfere with cross-correction mediated by
enzyme secreted from transduced cells.
In this study we demonstrated that intrathecal AAV9 delivery can effectively
target cells throughout the CNS in dogs and achieve sufficient expression to correct the
biochemical and histological abnormalities associated with MPS I in the brain of a large
animal. Previous work has demonstrated that even doses of intrathecal AAV9 much
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greater than those employed in this study result in transduction of a small fraction of
cells in the canine brain, suggesting that the widespread reduction in storage pathology
observed was due to cross-correction by secreted enzyme (Haurigot et al. 2013).
However, of the three animals treated with intrathecal vector alone, two developed
sufficiently robust anti-transgene antibody responses to prevent complete resolution of
CNS storage lesions. Only the animal that maintained near-normal CSF IDUA activity
after antibody induction to the transgene demonstrated a complete response to CNS
gene therapy. From this outcome, we conclude that IDUA activity in CSF is a reasonable
predictor of efficacy following intrathecal gene transfer, with approximately normal levels
required for full therapeutic benefit. This is consistent with our findings with intrathecal
gene therapy in MPS I cats(Hinderer, Bell, et al. 2014c). MPS I cats generally exhibited
weaker antibody responses to intrathecal gene transfer and more stable CSF IDUA
activity than MPS I dogs. This may relate to the underlying mutation in the two models,
as MPS I cats express an inactive mutant IDUA, potentially rendering them partially
immunologically tolerant to the enzyme. Importantly, the present data in MPS I dogs
indicate that even for MPS I patients with severe disease who, like the dogs, have no
residual IDUA expression, the anti-transgene antibody response that may occur after
intrathecal gene transfer does not result in adverse clinical events, and substantial
efficacy is retained despite the antibody response. However, these data also suggest
that preventing antibody responses against IDUA in the CNS could improve the efficacy
of intrathecal gene therapy for MPS I.
Using liver-directed gene transfer, we tested the effect of early exposure to IDUA
on subsequent immune responses following intrathecal gene therapy. Neonatal IDUA
expression induced tolerance to the enzyme in MPS I dogs, which markedly increased
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CSF enzyme levels achieved with intrathecal gene therapy at one month of age. The
high CSF IDUA levels in the immune tolerant group consistently resulted in complete
reversal of neuropathology, providing a strong example of the efficacy that is possible
with intrathecal gene therapy for LSDs when interfering antibody responses are
overcome. The finding that this neonatal window for induction of immune tolerance to a
transgene also exists in nonhuman primates appears promising for translation to the
clinic. Interestingly, neutralizing antibodies were elicited against the vector capsid in
newborn NHPs, demonstrating that while neonates may be relatively tolerant to foreign
proteins, they are fully capable of eliciting functional immune responses to pathogens.
This finding has important clinical implications; while neonatal gene transfer may provide
a method to circumvent immunity to the transgene, it does not provide a means of
avoiding the antibody response to the AAV capsid. Thus vector readministration—a
likely necessity in the setting of a life-saving gene therapy administered to a newborn—
will depend on the development of alternative serotypes or other methods to evade
capsid antibodies. In the case of intrathecal AAV delivery, readministration may be
possible due to the remarkable insensitivity of this approach to pre-existing capsid
antibodies (Haurigot et al. 2013).
Previous studies in mice, cats, and nonhuman primates have demonstrated
vector escape to the peripheral circulation following intrathecal AAV delivery, often
resulting in significant hepatic gene transfer and therapeutic levels of systemic transgene
expression (Hinderer, Bell, et al. 2014c, Hinderer, Bell, Vite, et al. 2014, Haurigot et al.
2013). We did not directly evaluate somatic disease correction in treated MPS I dogs
due to the confounding effects of anti-IDUA antibodies in the naïve cohort or previous
systemic gene transfer in the immune-tolerant cohort. Notably we observed minimal
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hepatic gene transfer following intrathecal AAV9 injection, consistent with the relatively
low permissivity of canine liver to AAV-mediated transduction(Bell et al. 2011). Given
the low level of hepatic gene transfer and serum IDUA activity in treated dogs,
improvement in somatic disease is unlikely. However it should be emphasized that this
inefficient peripheral transduction is inconsistent with that observed following intrathecal
AAV delivery in other species, and may be specific to the canine model.
There are several limitations of the present study. Due to the increased risks
associated with performing intrathecal vector injections in newborn MPS I pups, we
chose to use systemic gene transfer as a means of inducing tolerance rather than
performing CNS directed gene therapy in neonates. We therefore cannot conclude
whether route of administration plays a role in the induction of tolerance. Hepatic gene
transfer has often been associated with transgene specific tolerance, although we
observed antibody responses against IDUA in 3-month-old MPS I dogs treated with
AAV8-mediated hepatic gene therapy, indicating that liver directed gene transfer alone is
insufficient to induce tolerance in this model (Crudele et al. 2015, Finn et al. 2010,
LoDuca, Hoffman, and Herzog 2009, Sun et al. 2010). In this study we also did not rule
out the possibility that prior liver directed gene therapy contributed to the improved
correction of brain pathology in immune tolerant animals, although this appears unlikely
given that IDUA was undetectable in CSF in these animals at the time of intrathecal
vector injection, and CSF Hex activity and pGAG concentration showed no evidence of
correction before intrathecal gene transfer. This is consistent with our studies in MPS I
cats, in which even extremely high serum IDUA activity had no impact on brain lesions
(Hinderer, Bell, et al. 2014b). Additionally, while we focused this study entirely on the
observation of neonatal tolerance and its potential utility for therapeutic applications, we
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did not evaluate the mechanisms responsible for this phenomenon. This model could
serve as a powerful tool for better understanding the development of immunological
recognition of self and non-self, and future studies should explore possible mechanisms.
Finally, the present study did not define the temporal window in which tolerance
induction is possible. Based on the observation that detectable antibody responses
began to appear in the MPS I dogs treated on postnatal day 7, we estimate that this
period lasts no more than one to two weeks, which could serve as a useful starting point
for human studies.
If human neonates are found to exhibit the same potential for transgene-specific
immunological tolerance that we have demonstrated in dogs and nonhuman primates,
neonatal gene transfer could have enormous potential to treat many genetic disorders
for which immune responses limit the safety or efficacy of therapy. In order for clinical
trials to be feasible, newborn screening will be essential for identifying patients
sufficiently early for this approach to be effective. For MPS I, newborn screening is now
being implemented in several states, providing a potential opportunity to conduct first-inhuman trials (Hopkins et al. 2014).
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Figure 4-1. Neonatal systemic IDUA gene transfer induces tolerance to subsequent
CNS gene therapy in MPS I dogs. MPS I dogs were treated with an intrathecal injection
of an AAV9 vector encoding canine IDUA at one month of age (I-550, I-553, I-554) or
were first treated with an intravenous injection of an AAV8 vector encoding IDUA under
control of a liver specific promoter on postnatal day 1 (I-549, I-552) or postnatal day 7 (I562, I-563, I-564) followed by intrathecal vector injection at one month of age. (a) CSF
was serially collected from treated animals and assayed for IDUA enzyme activity. The
dotted line represents the mean CSF IDUA activity in normal control animals. (b)
Antibodies against canine IDUA were detected in CSF samples at baseline and on day
80 after intrathecal vector injection by indirect ELISA. Error bars represent standard error
of replicate wells. The dashed line is the upper limit of pretreatment samples.
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Figure 4-2. Biochemical markers are normalized following intrathecal gene therapy in
MPS I dogs. (a) CSF samples from treated dogs and untreated controls were analyzed
for Hexosaminidase (Hex) activity at the time of intrathecal vector injection (pre) and at
the time of tissue harvest (post). The dotted line indicates the upper limit of CSF Hex
activity in normal control samples. (b) Hex activity was also measured in brain lysates.
Values are the mean +/- SEM of samples collected from six brain regions (frontal cortex,
temporal cortex, occipital cortex, hippocampus, medulla, cerebellum). (c) Pathogenic
GAGs were measured in CSF at the time of intrathecal vector injection and on day 21
and 112 post injection.
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Figure 4-3. CNS storage lesions are more effectively cleared by intrathecal gene
therapy in MPS I dogs tolerized to IDUA as neonates. (a) Representative brain sections
are shown for normal, untreated MPS I, and tolerized intrathecal treated MPS I dogs. For
the three animals treated with AAV9 alone, images are shown for each animal.
Immunostaining was performed on cortical brain sections for the ganglioside GM3 and
the lysosomal membrane protein LIMP2. Unesterified cholesterol was detected by filipin
stain. GAG storage in meninges is stained with Alcian blue. Scale bar = 200 µM. (b)
Automated quantification was performed on GM3, and (c) LIMP2, and filipin stained
sections. Values are the mean +/- SEM of 10 sections.
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Figure 4-4. Neonatal gene transfer induces tolerance in nonhuman primates. Four
newborn rhesus monkeys were administered an AAV8 vector expressing either human
IDUA (Animal #s 1 and 2) or human factor IX (3 and 4) intravenously. All animals were
administered AAV9 expressing human IDUA using the intrathecal approach at 1 month
postnatal age. (a) IDUA activity was measured in CSF after intrathecal vector injection
weekly then monthly. The dotted line represents the mean IDUA activity in pretreatment
CSF samples. (b) Antibodies were detected in CSF by indirect ELISA 2 months after
intrathecal vector administration. The dashed line indicates the upper limit of baseline
samples. Error bars represent SEM.
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Fig 4-5: Serum IDUA activity in MPS I dogs. MPS I dogs were treated with an
intravenous injection of an AAV8 vector encoding canine IDUA under control of a liver
specific promoter on postnatal day 1 (I-549, I-552) or postnatal day 7 (I-562, I-563, I-564)
followed by intrathecal injection of an AAV9 vector at one month of age. Serum was
serially collected from treated animals and assayed for IDUA enzyme activity.
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Fig 4-6. Serum IDUA activity in rhesus monkeys.
Newborn rhesus macaques were administered an AAV8 vector intravenously expressing
human IDUA (animal 1 and 2) or human factor IX (3 and 4). All four were administered
an intrathecal injection of an AAV9 vector expressing human IDUA at one month of age.
Serum was serially collected from treated animals and assayed for IDUA enzyme
activity.
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Table 4-1. Summary of Study Subjects

MPS
dogs

Animal
ID

Genotype

IV vector

Age at IV
treatment
(days)

IT vector

Age at IT
treatment
(days)

Age at
necropsy
(months)

I-550

MPS I

-

-

AAV9.CB.cIDUAC

28

9

I-553

MPS I

-

-

AAV9.CB.cIDUA

28

9

I-554

MPS I

-

-

AAV9.CB.cIDUA

28

9

I-549

MPS I

AAV8.TBG.cIDUAA

1

AAV9.CB.cIDUA

28

9

I-552

MPS I

AAV8.TBG.cIDUA

1

AAV9.CB.cIDUA

28

9

I-562

MPS I

AAV8.TBG.cIDUA

7

AAV9.CB.cIDUA

28

11

I-563

MPS I

AAV8.TBG.cIDUA

7

AAV9.CB.cIDUA

28

11

I-564

MPS I

AAV8.TBG.cIDUA

7

AAV9.CB.cIDUA

28

11

I-497

MPS I

-

-

-

-

12

I-498

MPS I

-

-

-

-

12

I-500

MPS I

-

-

-

-

12

I-503

MPS I

-

-

-

-

12

I-504

MPS I

-

-

-

-

12

I-343

MPS I

-

-

-

-

18

I-416

MPS I

-

-

-

-

6

I-472

MPS I

-

-

-

-

18

I-421

Normal

-

-

-

-

26

DM154

Normal

-

-

-

-

12

1

Normal

AAV8.TBG.hIDUAB

1

AAV9.CB.hIDUAD

30

ongoing

2

Normal

AAV8.TBG.hIDUA

1

AAV9.CB.hIDUA

30

ongoing

3

Normal

AAV8.TBG.hFIX

1

AAV9.CB.hIDUA

30

ongoing

4

Normal

AAV8.TBG.hFIX

1

AAV9.CB.hIDUA

30

ongoing

I

Rhesus
macaques

A. 5 x 1012 genome copies per kilogram (GC/kg); IV=intravenous; IT=intrathecal
B. 1012 GC/kg
C. 1012 GC/kg

D. 3 x 1012 GC/kg

102

Table 4-2: CSF nucleated cell counts in MPS I dogs following vector injection
(Cells/µL)

Day
post IT
vector
Animal No.

0

7

21

51

81

549

1

ND

2

0

0

550

2

ND

11A

BC

2

552

0

ND

ND

2

2

553

2

ND

1485C

2

2

554

0

ND

14B

1

2

562

2

BC

1

0

0

563

BC

1

29B

1

0

564

1

1

4

0

0

ND = not done, BC = Blood contamination of CSF
sample (>500 erythrocytes/µL), IT=intrathecal.
Normative range ≤ 5 cells/µL.

A. 317 erythrocytes/µL
B. >70% lymphocytes
C. >70% monocytes
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Table 4-3: Vector biodistributionA

I-550

I-553

I-554

I-549

I-552

I-562

I-563

I-564

Frontal cortex

0.207224

0.032837

0.037931

0.195879

0.311028

0.053383

0.014606

0.41984

Temporal cortex

0.324461

0.015715

0.042556

0.682856

0.024615

0.075457

0.539041

0.541367

Occipital cortex

0.240198

0.03092

0.068607

0.585868

0.158689

0.006249

0.021576

0.724321

Hippocampus

0.007486

0.032587

0.058214

0.008692

0.336849

0.01288

0.056152

0.065506

Medulla

0.156078

0.012703

0.004936

0.063498

0.194763

0.294345

0.032355

0.020695

Cerebellum

0.022631

0.014178

0.010712

0.061944

0.046369

0.025023

0.026128

0.02586

Spinal cord
cervical

0.257116

0.034117

0.014234

0.165666

0.509951

0.510722

0.046194

0.093024

Spinal cord
thoracic

0.43775

0.063695

0.02829

0.359055

0.140467

0.120746

0.079992

0.100718

Spinal cord
lumbar

0.190243

0.03037

0.116436

0.460682

0.313737

0.225627

0.241252

0.263238

Heart

0.001076

<0.0005B

0.001983

0.00145

0.001454

0.02967

0.005545

0.005753

Lung

0.000879

0.002424

0.001887

0.000491

0.000538

0.000667

0.001105

0.001883

Liver

0.001304

0.004242

0.001918

0.010545

0.206071

0.030681

0.006334

0.028654

Spleen

0.002579

0.001543

0.001228

0.002596

0.002229

0.044439

0.003144

0.008972

A. Values are genome copies (GC) per diploid genome. The assay does not distinguish between the AAV8 and AAV9
vectors.
B. Limit of detection
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CHAPTER 5: Induction of transgene-specific immune tolerance
enables evaluation of a human gene therapy for
mucopolysaccharidosis type I in an authentic dog model

Chapter 5 is adapted from the manuscript: C. Hinderer, P. Bell, J. P. Louboutin, Y. Zhu,
H. Yu, G. Lin, R. Choa, B. L. Gurda, J. Bagel, P. O'Donnell, T. Sikora, T. Ruane, P.
Wang, M. L. Casal, M. E. Haskins, J. M. Wilson. In preparation.
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Abstract:
High fidelity animal models of human disease are essential for preclinical
evaluation of novel gene and protein therapeutics.

However, these studies can be

complicated by exaggerated immune responses against the human protein that preclude
meaningful assessment of safety and efficacy. Here we demonstrate that dogs with a
genetic deficiency of the enzyme α-l-iduronidase (IDUA), a model of the neuropathic
lysosomal storage disease mucopolysaccharidosis type I (MPS I), can be rendered
immunologically tolerant to human IDUA through neonatal exposure to the enzyme.
Using MPS I dogs tolerized to human IDUA as neonates, we evaluated intrathecal
delivery of an adeno-associated virus serotype 9 vector expressing human IDUA as a
therapy for the central nervous system manifestations of MPS I.

These studies

established the efficacy of the human clinical candidate vector in the canine model, and
allowed for estimation of the minimum effective dose, providing key information for the
design of first in human trials. This approach has considerable potential to facilitate
evaluation of human therapeutics in relevant animal models. If the neonatal tolerance
induction strategy employed can be translated to humans, it may also have clinical
applications for the prevention of immune responses to gene and protein replacement
therapies.

Introduction
Mucopolysaccharidosis type I (MPS I) is a rare inherited lysosomal storage
disease caused by deficiency of IDUA, an enzyme required for the catabolism of
ubiquitous glycosaminoglycans (GAGs). GAG accumulation leads to a variety of clinical
manifestations including bone and joint deformities, corneal clouding, and cardiac valve
insufficiency. MPS I patients frequently experience neurological complications including
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communicating hydrocephalus and spinal cord compression. The impact of the disease
on cognitive function varies; in the attenuated form of MPS I (Scheie syndrome or
Hurler-Scheie syndrome) in which there is residual IDUA activity, cognition is affected in
only about one third of patients. In the more common severe form of MPS I (Hurler
syndrome), patients universally exhibit rapid cognitive decline in early childhood(Wraith
et al. 2007). MPS I is currently treated with intravenous infusion of the recombinant
enzyme, which can be internalized by cells from the circulation via mannose 6phosphate receptor binding (Sando and Neufeld 1977, Dahms, Lobel, and Kornfeld
1989). Enzyme replacement improves many disease symptoms, but does not reach the
CNS, and therefore has no impact on cognitive function (Wraith et al. 2007). MPS I can
also be treated with hematopoietic stem cell transplantation (HSCT) which provides a
constant source of circulating IDUA through enzyme secretion by engrafted donor cells.
Unlike enzyme replacement, HSCT can improve cognitive outcomes, apparently due to
migration of donor derived cells across the blood-brain barrier, where they serve as a
source of secreted enzyme within the CNS. However, HSCT suffers from numerous
complications including graft failure, infection, graft versus host disease, and transplantassociated mortality as high as 20%(Aldenboven, Boelens, and de Koning 2008,
Boelens et al. 2007, Braunlin et al. 2003, de Ru et al. 2011, Souillet et al. 2003, Staba et
al. 2004, Whitley et al. 1993).

After transplant many patients also exhibit residual

cognitive deficits, which may be a consequence of disease progression during the slow
engraftment of donor cells in the CNS (Kennedy and Abkowitz 1997).

These

shortcomings leave a significant unmet need for a safe and effective therapy for the CNS
manifestations of MPS I.

107

Gene therapy is a promising alternative to HSCT for the treatment of cognitive
decline in MPS I patients. Gene transfer has the potential to induce rapid reconstitution
of IDUA in the CNS without the adverse effects of HSCT, and targeting even a small
number of cells in the CNS could provide a depot of secreted IDUA in the brain, leading
to widespread improvement of storage pathology. We previously demonstrated that
injection of an adeno-associated virus serotype 9 vector into the cerebrospinal fluid
(CSF) can efficiently deliver the IDUA gene to cells throughout the CNS, and that the
enzyme secreted by transduced cells mediates global resolution of brain storage lesions.
These proof-of concept studies for intrathecal AAV9 gene therapy relied on two naturally
occurring large animal disease models, the MPS I dog and MPS I cat. The use of these
models was critical for evaluating the efficacy of the approach, not only because they
accurately reproduce the CNS pathology of MPS I, but also because these large animals
better reflect the human CNS anatomy and CSF circulation than rodent models, allowing
for realistic representation of the clinical route of administration and the resulting vector
distribution. While these initial experiments in the MPS I dog and cat were carried out
using vectors expressing species-specific transgenes, advancing this approach toward
human trials necessitated the evaluation of a clinical candidate vector bearing the
human IDUA transgene. However, studies of the clinical candidate vector in the MPS I
dog model were complicated by an exaggerated immune response to the human
enzyme.

Building on our previous finding that neonatal gene transfer could induce

persistent tolerance to the transgene product, we applied this approach to induce
tolerance to human IDUA in MPS I dogs, which subsequently allowed for the evaluation
of the efficacy of the human vector in this model.
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Materials and Methods
Vector production:

A codon optimized human IDUA cDNA was cloned into an

expression construct bearing the cytomegalovirus immediate early enhancer, chicken
beta-actin promoter and rabbit globin polyadenylation sequence flanked by AAV2
inverted terminal repeats. The construct was packaged in an AAV9 capsid, purified and
titered as previously described.
Animal procedures:
The MPS I dog colony was maintained at the University Of Pennsylvania School Of
Veterinary Medicine under NIH and USDA guidelines for the care and use of animals in
research. All study protocols were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee.

For infusions of recombinant human

IDUA, laronidase (Genzyme) was diluted 5 –fold in saline immediately before use.
Infusions were performed through a peripheral venous catheter over two hours. Vector
injections, serum and CSF collection, and euthanasia were performed as previously
described(Hinderer et al. 2015).
Enzyme assays:
IDUA and Hex activity were measured in tissue lysates and CSF as previously
described(Hinderer, Bell, et al. 2014c).
Anti-hIDUA ELISA:
Polystyrene ELISA plates were coated overnight at 4 degrees with recombinant human
IDUA (Genzyme) diluted to 5micrograms/mL in phosphate buffer pH 5.8. The plate was
washed and blocked in 2% BSA in phosphate buffer. The plate was incubated 1 hour at
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room temperature with CSF samples diluted 1:50 in PBS. The plate was washed and
bound antibody detected with HRP conjugated anti-canine IgG (Pierce, Rockford, IL)
diluted 1:10,000 in 2% BSA.

The ELISA was developed with tetramethylbenzidine

substrate for 15 minutes, then stopped with 2 N sulfuric acid and absorbance was
measured at 450 nm. Titers were calculated from a standard curve of a serially diluted
positive sample.
Histology:
Tissue processing, immunostaining and quantification were performed as previously
described (Hinderer et al. 2015).
Biodistribution:
Vector biodistribution was evaluated as described (Hinderer et al. 2015).

Results
Intrathecal AAV9 expressing human IDUA elicits robust transgene-specific immunity in
MPS I dogs
Five MPS I dogs were treated at one month of age with a single intrathecal
injection into the cisterna magna of an AAV9 vector expressing human IDUA. Vector
doses ranged from 1011 genome copies per kg (GC/kg) to 1012 GC/kg. The procedure
was well tolerated in all subjects. IDUA activity in CSF rapidly increased following vector
administration, exceeding that of normal controls by day 7 (Figure 5-1). However, by
day 21 post vector administration CSF IDUA levels fell to baseline, accompanied by an
elevation in CSF anti-hIDUA titers (Figure 5-2). Day 21 CSF samples also revealed a
lymphocytic pleocytosis in all animals (Figure 5-3A). In these cohorts the elevated CSF
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antibodies and cell counts were not associated with clinical signs or other laboratory
abnormalities, and the pleocytosis spontaneously resolved. At the time of necropsy six
months after injection, histological evaluation revealed no evidence of pathology in the
brain or spinal cord. Vector biodistribution demonstrated widespread CNS transduction
and persistence of the vector genome (Table 5-1).

Histology also showed some

improvement in brain storage lesions (Figure 5-7).
Based on the favorable safety profile observed in these dogs we dosed an
additional two MPS I dogs with a 10-fold higher dose of vector (i.e., 1013 GC/kg). These
dogs developed CSF pleocytosis with similar kinetics to the animals treated at the lower
two doses; however in these two subjects the response was more pronounced, and the
pleocytosis was temporally associated with the onset of neurological signs. Beginning
21 days after vector administration, the animals exhibited hyporeflexia and weakness of
the hind limbs, and pain upon flexion of the neck.

The animals were treated with

corticosteroids and analgesics, after which the pain and CSF pleocytosis began to
resolve. However, the hind limb weakness persisted, and the animals were euthanized
two weeks after symptom onset. Histopathology demonstrated robust transduction of
spinal motor neurons, particularly in the lumbar spinal cord, and lymphocytic infiltrates
surrounding transduced neurons (Figure 5-4).

Immunostaining revealed that the

infiltrating mononuclear cells consisted primarily of B cells, with occasional CD4 and
CD8 T cells infiltrating the associated spinal nerves. The correlation between the clinical
signs of hind limb weakness and the histological evidence for high levels of transgene
expression in the lumbar spinal motor neurons and selective lymphocytic infiltration at
this level suggests that neurological toxicity was driven by a transgene specific immune
response targeting heavily transduced motor neurons. An interferon gamma ELISPOT
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assay performed on PBMCs collected at necropsy was negative for T cell responses to
the transgene or the vector capsid (data not shown) although these results may be
confounded by the preceding course of corticosteroids.
Neonatal exposure to human IDUA through hepatic gene transfer induces tolerance to
subsequent intrathecal gene transfer
In order to evaluate the AAV9 vector expressing human IDUA in the absence of
an exaggerated immune response to the human protein, 6 MPS I dogs were tolerized to
human IDUA with a single intravenous injection of an AAV serotype 8 vector expressing
human IDUA from a liver specific promoter on postnatal day 5. At one month of age the
animals were treated with different doses of an intrathecal injection of the AAV9 vector
expressing human IDUA in three cohorts (N=2 animals per cohort) as follows: 1010, 1011
and 1012 GC/kg. All animals exhibited dose-dependent elevation in CSF IDUA activity
similar to the non-tolerized dogs; however, in this cohort CSF enzyme expression
persisted beyond day 21 and remained relatively stable for the duration of the
experiment (Figure 5-1). CSF antibody responses were blunted compared to what was
observed when naïve (i.e., non-tolerized animals) were dosed with intrathecal vector,
with only two animals of the tolerized cohorts (I-602 and I-606) exhibiting detectable
titers, which were approximately 20 fold lower than naïve animals treated with an
equivalent vector dose (Figure 5-2). Only the dog with the highest antibody titer in this
cohort exhibited elevated CSF lymphocytes at day 21, albeit at lower levels than in the
naïve animals (Figure 5-3). There were no clinical adverse events in these cohorts.
Intrathecal AAV9-mediated hIDUA expression effects dose-dependent correction of
brain biochemical abnormalities and storage lesions
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The MPS I dog carries an IDUA mutation resulting in inclusion of the first intron in
the mature mRNA, creating an immediate stop codon. The mutation in MPS I dogs
yields no detectable IDUA activity (Menon, Tieu, and Neufeld 1992, Terlato and Cox
2003, He et al. 1999). In the absence of lysosomal IDUA activity, undegraded GAGs
accumulate in the cell (Sando and Neufeld 1977). This primary GAG storage material in
affected tissues can be directly detected histologically by Alcian blue staining (Shull et al.
1984, Shull et al. 1994, Clarke et al. 2009, Ellinwood et al. 2007, Haskins et al. 1983,
Terlato and Cox 2003, Chen et al. 2011, Hinderer, Bell, et al. 2014c). In addition to the
primary GAG storage pathology, lysosomal GAG accumulation leads to a characteristic
cascade of cellular abnormalities. The un-degraded GAGs cause lysosomal distention,
visible on histology by increased staining for lysosomal membrane proteins such as
LIMP2.

Neurons also exhibit secondary accumulation of substances such as

gangliosides (e.g. GM3) and un-esterified cholesterol. These secondary storage
materials can be detected by microscopy using immunostaining (GM3) or filipin staining
(cholesterol). Lysosomal storage also induces aberrant overexpression of lysosomal
enzymes such as hexosaminidase.
The six MPS I dogs tolerized to human IDUA through neonatal gene transfer
were sacrificed 6 months post intrathecal AAV9 injection. Brain lysates demonstrated
normalization of hexosaminidase activity, which correlated with vector dose (Figure 5-5).
Hexosaminidase activity was normalized in CSF at all vector doses (Figure 5-8). There
were also dose-dependent decreases in LIMP2 and ganglioside storage (Figure 5-6).
CNS pathology was almost completely reversed at the highest vector dose.

At the

lowest dose, there were measurable improvements in some markers (LIMP2 and Hex)
whereas ganglioside accumulation was not clearly reduced. The low dose of 1010 GC/kg
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therefore appeared to be the minimum effective dose. Scaled to the 45g brain mass of a
one-month old dog, and with an average body weight of 2 kg, this dose would
correspond to an MED of 4.4 x 108 GC/g brain mass, or approximately 6.2 x 1011 GC in
an adult human.
Infusion of recombinant hIDUA in newborn MPS I dogs is sufficient to induce tolerance
to intrathecal AAV9-mediated hIDUA expression
In order to determine whether hepatic expression of human IDUA was necessary
for tolerance induction, we treated two MPS I dogs (I-663 and I-664) with infusions of
recombinant human IDUA (0.58 mg/kg) on postnatal day 7 and 14 before intrathecal
AAV9 injection at one month of age. Similar to dogs treated as newborns with a vector
expressing human IDUA, the enzyme treated dogs exhibited persistently high levels of
CSF IDUA activity (Figure 5-1) and no antibody response against human IDUA (Figure
5-2) or CSF pleocytosis (Figure 5-3). Brain storage lesions were effectively cleared in
both animals (Figure 5-6).
Discussion
Evaluating the efficacy of intrathecal AAV9 delivery for the treatment of MPS I
required assessment of both the vector distribution that could be achieved via injection
into the CSF, and the impact of that degree of transduction on measures of disease
activity. These studies necessitated the use of an animal model that could accurately
reflect the disease pathophysiology while also displaying sufficiently similar size and
anatomy to allow for meaningful evaluation of the clinical delivery method and the
resulting vector distribution. The canine model of MPS I faithfully replicates the human
phenotype, exhibiting not only the same biochemical and histological lesions, but also
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many of the same clinical manifestations (Ciron et al. 2006, Dickson, Ellinwood, et al.
2010, Dickson et al. 2009, Menon, Tieu, and Neufeld 1992, Shull et al. 1984, Shull et al.
1994, Traas et al. 2007). Due to the phenotypic similarity to MPS I in humans, MPS I
dogs were used extensively in the development of enzyme replacement therapy for the
treatment of systemic disease (Dickson, Peinovich, et al. 2008, Shull et al. 1994). MPS I
dogs also mimic CNS manifestations of the disease, sporadically developing spinal cord
compression and hydrocephalus (Dickson, Ellinwood, et al. 2010, Dickson et al. 2009,
Vite et al. 2013). Though cognitive studies have not been reported for MPS I dogs, the
histological and biochemical manifestations in the brain have been well characterized,
and faithfully recapitulate the findings in humans with the severe from of the disease
(Ciron et al. 2006, Shull et al. 1984, Walkley, Haskins, and Shull 1988). MPS I dogs
demonstrate accumulation in the brain of lysosomal membrane proteins (LIMP2) and
gangliosides (GM3), and upregulation of lysosomal enzymes such as hexosaminidase
(Hex). Ganglioside accumulation correlates with cognitive function in MPS I and other
lysosomal storage diseases, and thus is a critical marker for evaluating disease severity
and therapeutic outcomes (Walkley and Vanier 2009, Constantopoulos, Iqbal, and
Dekaban 1980). MPS I dogs also exhibit changes in neuronal morphology like those
identified in patients (Walkley, Haskins, and Shull 1988).

These striking similarities

between this model and MPS I patients made this a compelling model for the evaluation
of intrathecal AAV delivery as novel therapy for the CNS manifestations of the disease.
The capacity of large animal models to replicate the route of administration that would be
used clinically for IT AAV9 delivery, as well as the resulting vector distribution in the
CNS, further supported the relevance of the MPS I dog for these studies.
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Although the MPS I dog appeared to be an excellent model for evaluation of the
clinical vector, the immune response to human IDUA presented a critical obstacle. From
previous studies it is clear that the immune response to human IDUA in MPS I dogs is
much more extreme than that observed in patients. Intravenous delivery of the protein in
both dogs and MPS I patients often results in the development of serum antibodies;
however in dogs these responses are more robust, less likely to decline upon continued
administration, and more often associated with anaphylactic responses to subsequent
infusions (Kakkis, Lester, et al. 2004, Shull et al. 1994). The difference in immune
response to human IDUA in the CNS is even more striking; in MPS I dogs treated with
intrathecal infusions of laronidase there was evidence of meningitis in addition to
antibody responses detectable in CSF; in both pediatric and adult MPS I patients treated
with repeated IT infusions of the protein there have been no similar adverse effects, and
in the 5 patients that have been tested for CSF antibodies against IDUA only one has
been positive(Chen et al. 2011, Dickson, Ellinwood, et al. 2010, Dickson et al. 2009,
Dickson, Hanson, et al. 2010, Dickson, Naylor, Mlikotic, Victoroff, Chen, Passage, Le, et
al. 2008, Kakkis, McEntee, et al. 2004, Lund et al. 2014, Vera et al. 2013). Interestingly
MPS I dogs also develop antibodies to canine IDUA, albeit at lower levels than to the
human enzyme, suggesting that this model has a greater overall tendency toward
immunity to IDUA which is exacerbated by the use of the non-species specific protein
(Hinderer et al. 2015). These marked differences in the outcome of both intravenous
and intrathecal delivery of human IDUA in MPS I dogs and patients indicate a
consistently exaggerated immune response to human IDUA in MPS I dogs, and suggest
that preventing this response will be necessary to replicate the anticipated vector activity
in humans. Inducing tolerance to the protein through neonatal exposure allowed for the
evaluation of the efficacy of the human vector in this model without the interference of
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the exaggerated immune response. This provided critical information, allowing for the
determination of the minimum effective dose—an essential factor in the design of first-in
human gene therapy trials—in the most relevant animal model. Without this approach,
the only options would be to extrapolate efficacy data from vectors with species specific
transgenes, which could have important differences in potency, or move studies to a less
representative animal model that is more immune tolerant to the human protein.
Pharmacologic immune suppression can also be employed in this setting, although the
neonatal tolerance induction protocol has the clear advantage of avoiding secondary
consequences of the immune suppressing drugs.
Though efficacy assessment was confounded by the immune response and loss
of circulating IDUA in the non-tolerized dogs treated with the human vector, some useful
data can be derived from these animals. While the strong immune response is not likely
to represent the immune response in humans, it could inform monitoring plans for first in
human studies by demonstrating key characteristics of immune-mediated toxicity. In this
case we saw that immune-mediated toxicity was dose-dependent, the peak of the
immune response occurred 3 weeks after vector administration, presented with focal
motor symptoms likely due to high transduction of spinal motor neurons, and was
accompanied by CSF pleocytosis. These findings could be directly integrated into the
phase 1 trial protocol, with intensive monitoring for immune-mediated toxicity and
neurological symptoms extending for several weeks after vector administration, and CSF
analysis for pleocytosis occurring 3-4 weeks after injection. If neurological symptoms
accompanied by pleocytosis appeared with similar kinetics in a human study subject, the
findings in naïve dogs would suggest that the toxicity is due to an immune response (as
opposed to overexpression toxicity, for example) and could guide therapeutic decisions.
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The present findings indicate that neonatal exposure to human IDUA can induce
tolerance regardless of the source of the enzyme. While we had previously found that
AAV-mediated expression could induce tolerance in neonates, here we found that
infusion of the recombinant enzyme could also induce tolerance. If this approach is
generalizable to other proteins, it could be useful for preclinical evaluation of many
human therapeutics in animal models.

Further, if a similar approach could induce

tolerance to foreign proteins in human neonates, it could have enormous potential to
improve the efficacy of protein replacement therapies for diseases in which antibody
responses to the normal protein limit efficacy. In the case of MPS I, while most patients
appear to tolerate intrathecal IDUA infusions, the vast majority develop serum antibodies
against intravenous enzyme replacement, and these antibodies can diminish the
response to therapy. Combining neonatal tolerance induction with a gene or protein
replacement therapy may substantially improve patient outcomes. The availability of an
approved recombinant enzyme would make MPS I an excellent candidate for an initial
human trial of this approach. If human neonates exhibit the same window of 1-2 weeks
for tolerance induction, newborn screening would be essential for identifying patients
early enough for successful intervention.

The ongoing implementation of newborn

screening for MPS I and other lysosomal storage diseases will therefore be critically
important for clinical evaluation of a neonatal tolerance induction protocol.
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Figure 5-1. CSF IDUA activity in MPS I dogs treated with intrathecal AAV9 expressing
human IDUA. Dogs were treated at one month of age with an intrathecal injection of the
vector into the cisterna magna. IDUA activity was measured in subsequent CSF
samples.

Vector doses (GC/kg) are indicated for each animal.

The dashed lines

represent animals treated with intrathecal vector only. The solid lines with filled symbols
represent animals pretreated on postnatal day five with intravenous AAV8 expressing
human IDUA from a liver-specific promoter. Solid lines with open symbols represent
animals pretreated on postnatal day 7 and 14 with intravenous infusion of recombinant
human IDUA. Animals I-665 and I-666 were euthanized on day 36 due to neurological
signs. The dotted line represents mean CSF IDUA activity in normal dogs.
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Figure 5-2. CSF antibody titer against human IDUA. Antibody titers against human
IDUA were measured by ELISA in CSF samples collected 50 days post vector
administration. CSF samples tested from I-665 and I-666 were collected at the time of
necropsy (day 36 post injection). The dashed line represents the upper limit of CSF
antibody titers measured in naïve control dogs. Error bars = SEM. Antibody titers were
significantly lower in the animals pre-treated as neonates with AAV8 vector or
recombinant human IDUA compared to controls (Mann-Whitney test).
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Figure 5-3. CSF nucleated cell counts following intrathecal AAV9 injection. Total
nucleated cell counts were measured in CSF samples from naïve dogs treated with
intrathecal AAV9 (left panel) as well as animals treated as neonates with systemic IDUA
protein (I-663 and I-664) or IDUA expressing vector before receiving intrathecal AAV9
(right panel).

Figure 5-4. Lymphocyte infiltration of the lumbar spinal cord in MPS I dogs exhibiting
hind limb weakness

following human IDUA gene transfer. Representative sections of

the lumbar spinal cord (A,B) and lumbar spinal nerve (C-E) are shown for the two naïve
dogs (I-665 and I-666) treated with the highest dose of AAV9 expressing human IDUA.
Sections were stained with H&E (A) or immunostained for human IDUA (red) and CD20
(green) (B,C), CD4 (D), or CD8 (E).
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Figure 5-5. Normalization of brain hexosaminidase activity in human IDUA tolerant MPS
I dogs treated with intrathecal AAV9.

Hexosaminidase activity was measured in

samples collected from six brain regions (frontal cortex, temporal cortex, occipital cortex,
hippocampus, medulla and cerebellum). The mean activity is shown for a normal control
dog, untreated MPS I dogs, and the six hIDUA tolerant dogs treated with intrathecal
AAV9 expressing human IDUA.

Error bars = SEM. Hex activity was significantly

reduced in the high dose cohort compared to untreated controls (Kruskal-Wallis test
followed by Dunn’s multiple comparisons test).
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Figure 5-6. Dose-dependent correction of brain storage lesions in human IDUA tolerant
dogs treated with intrathecal AAV9. Brains were sectioned and stained for LIMP2 and
GM3 (A). Meningeal GAG accumulation was imaged using Alcian blue staining.
Automated quantification of GM3 (B) and LIMP2 (C) positive cells was performed on
cortical brain images (n = 10 per animal). Open symbols indicate animals tolerized with
infusion of recombinant human IDUA. GM3 and LIMP2 were significantly reduced in the
high dose cohort compared to untreated controls (Kruskal-Wallis test followed by Dunn’s
multiple comparisons test).
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Figure 5-7. Partial correction of brain storage lesions in dogs treated with intrathecal
AAV9 expressing human IDUA. Brains were sectioned and stained for LIMP2 and GM3.

Figure 5-8. Normalization of CSF hexosaminidase activity after IT AAV9 treatment. Hex
activity was measured in CSF of MPS I dogs tolerized to human IDUA at the end of the
study. The shaded region represents CSF hex acitivity in untreated MPS I dogs. The
dotted region indicates the normal range.
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Table 5-1. Vector biodistribution
Dose

1e10
GC /
kg

Animal
Number

Frontal
Cortex

Temporal
Cortex

†

0.0021

0.0043

0.0087

652

Occipital
Cortex

Hippocampu
s

Medulla

Cerebellum

Cervical
Spinal
Cord

Thoracic
Spinal
Cord

Lumbar
Spinal
Cord

Heart

Lung

Liver

Spleen

0.0620

0.0441

0.0980

0.0214

0.0123

0.0096

0.0170

0.0077

0.0022

0.0050

0.0015

0.0046

0.0008

0.0054

0.0044

0.0011

0.0020

0.0016

NA

‹0.0005

0.0025

0.0010

0.0014

0.0078

0.0122

0.0033

0.0112

0.0071

0.0008

0.0150

0.0129

0.0063

‹0.0005

‹0.0005

0.0016

0.0031

0.0480

0.0043

0.0031

0.0624

0.0087

0.0108

0.0025

0.0079

0.0063

‹0.0005

0.0005

0.0009

0.0014

0.0029

0.0178

0.0144

0.0011

0.1120

0.0006

0.0077

0.0012

‹0.0005

0.0054

0.0008

†

653

604

1e11
GC /
kg

608

†

602

0.0151

0.0033

†

607

0.0069

0.0079

0.0025

0.0041

0.0030

0.0012

0.0028

0.0039

‹0.0005

0.0008

‹0.0005

0.0013

0.0025

0.0153

0.0040

0.0166

0.0078

0.0325

0.0033

0.0447

0.2899

0.0592

0.0226

‹0.0005

0.0011

‹0.0005

0.1587

0.4328

0.1720

NA

0.1339

0.0113

0.1128

0.0701

0.0466

0.0013

‹0.0005

0.0010

0.0005

0.0831

0.1264

0.0725

0.0209

0.0682

0.0188

0.0531

0.0242

0.0663

0.0008

‹0.0005

0.0025

0.0027

0.3790

0.7676

0.2262

0.0324

0.0484

0.0518

0.7661

0.5163

0.6688

0.0110

0.0055

0.3554

0.1286

2.3428

0.4896

0.4006

NA

0.1169

0.0938

0.3797

1.5287

0.8769

0.0056

0.0008

0.2507

0.1418

†

605
1e12
GC /
kg

†

601

606

665
1e13
GC /
kg
666

† = Tolerized with 5e12 GC / kg hIDUA on postnatal day 5
NA = (sample) not analyzed
Limit of detection = 0.0005 GC/dg
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CHAPTER 6: General discussion
Three decades ago it was demonstrated that the coding sequences of the adenoassociated virus genome could be provided in trans, allowing for the generation of
infectious particles in which the endogenous genome was replaced with a transgene
(Samulski, Chang, and Shenk 1989, 1987). This discovery would revolutionize gene
therapy—for the first time it became possible to achieve in vivo gene transfer with a
vector that did not cause insertional mutagenesis, nor elicit destructive immune
responses against the transgene product. The emergence of AAV for in vivo gene
therapy left only two major challenges: a relatively limited packaging capacity of around
5 kb, and because of the non-integrating nature of the vector, only quiescent tissues
such as heart, skeletal muscle, liver, retina and brain could be stably transduced. The
past two decades have seen rapid development of AAV based therapies targeting these
tissues, with repeated demonstrations of efficacy in animal models. Targeting the retina
yielded one of the first clinical successes; subretinal delivery of an AAV vector
expressing RPE65 rescued vision loss in a canine model of Leber's congenital
amaurosis, and soon after demonstrated efficacy in children with the disease (Acland et
al. 2001, Bainbridge et al. 2008, Maguire et al. 2009).

Though many other early

successes in animal models of liver and muscle directed gene therapy couldn’t be
replicated in the clinic, the development of a second generation of more efficient vectors
made targeting these tissues a reality, leading to successful trials for hemophilia B and
lipoprotein lipase deficiency (Nathwani et al. 2011, Bryant et al. 2013, Gao et al. 2002,
Gao et al. 2004, Xiao et al. 1999).
Among the tissues initially targeted with AAV gene therapy, the brain has lagged
behind in terms of clinical success. Trials of AAV mediated gene transfer to the brain
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have demonstrated possible small benefits in Canavan disease and aromatic amino acid
decarboxylase (AADC) deficiency, and expression of AADC in the brain has been
demonstrated for several years after gene transfer by PET imaging (Mittermeyer et al.
2012, Janson et al. 2002, Leone et al. 2012, Hwu et al. 2012). While these studies and
others have established a strong safety profile for AAV in the brain, there has yet to be a
major clinical success for CNS-directed gene transfer. The primary obstacle to the field
has been delivery—injection into the brain requires an invasive neurosurgical procedure,
and can only transduce a small region surrounding the injection site (Vite et al. 2005).
Some diseases affecting a single brain nucleus may be responsive to localized injection
of the vector, but many genetic diseases affect cells throughout the CNS, making
localized delivery ineffective.

Studies in dog and cat models of genetic diseases

demonstrated that reasonably widespread correction could sometimes be achieved with
as few as 4-6 injections, however scaled from a 30-70 g cat or dog brain to a 1.4 kg
human brain, more than 100 injections would be required for equivalent breadth of
transduction (Vite et al. 2005, Ciron et al. 2006).

Vector injection into the brain

parenchyma can also induce inflammation that may elicit adaptive immune response to
the transgene product; in studies in both dogs and NHP, transduced cells surrounding
the injection site have been the target of T cell mediated killing (Ciron et al. 2006,
Samaranch, San Sebastian, et al. 2013).
A critical advance for CNS gene therapy was the discovery that some novel AAV
serotypes, particularly AAV9, could transduce neurons in the brain and spinal cord after
intravascular delivery (Foust et al. 2009). This made it possible for the first time to
achieve transduction of a large number of cells throughout the CNS without an invasive
procedure. Intravenous AAV9 delivery demonstrated remarkable success in a mouse
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model of spinal muscular atrophy (SMA), a disease affecting lower motor neurons
throughout the spinal cord (Foust et al. 2010). Treating newborn animals allowed for
transduction of a large fraction of spinal cord motor neurons, leading to increased
survival and improved motor function. This approach is now progressing into clinical
trials for SMA, as well as the lysosomal storage disease MPS IIIa. However, while
intravenous AAV9 delivery has been an important step for the field, CNS transduction is
much less efficient in large animals than in newborn mice, with very limited transduction
in the brain even at extremely large vector doses (Hinderer, Bell, Vite, et al. 2014, Bevan
et al. 2011, Gray et al. 2011). The resulting high levels of peripheral transduction limit
this approach to diseases in which the vector has no peripheral toxicity even at very high
doses. Intravenous AAV9 delivery is also very sensitive to the presence of pre-existing
capsid antibodies, limiting the number of patients eligible for therapy. This approach
may be clinically useful for select applications, but will not be sufficient for many
diseases affecting the CNS.
The shortcomings of both intraparenchymal and systemic AAV delivery for CNS
gene transfer have left a need for an efficient, non-invasive method to target a vector to
large regions of the CNS. Delivery into CSF seems a reasonable option, given that this
approach can theoretically achieve high vector concentrations in the CNS, and allow for
broad distribution throughout the brain and spinal cord. However, intrathecal delivery has
not often been pursued as a method for delivery of biologics to the CNS. This is rooted
in a widely held perception that there is minimal interaction between CSF and the brain
parenchyma, as the CSF is confined to the space between the arachnoid and the pia
mater covering the brain (Papisov, Belov, and Gannon 2013). However, many studies
have now demonstrated the exchange of CSF with brain interstitial fluid and the ability of
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macromolecules to distribute to the brain following intrathecal delivery (Iliff et al. 2013,
Iliff et al. 2012, Calias et al. 2012). This observation has extended to AAV vectors; there
have been multiple demonstrations of transduction in the brain and spinal cord after
intrathecal AAV delivery in mice, dogs, cats, and nonhuman primates (Haurigot et al.
2013, Gray et al. 2013, Samaranch, Salegio, et al. 2013, Hinderer, Bell, Vite, et al. 2014,
Bucher et al. 2014b). These studies demonstrated widespread transduction of both
neurons and glial cells throughout the brain following AAV9 delivery into the CSF.
Transduction in the brain was not associated with inflammation or immune responses
directed against transduced cells, as had been seen in some studies of
intraparenchymal injection. In addition to brain transduction, a very large proportion of
spinal cord motor neurons can be transduced by a single intrathecal vector injection.
This approach thus offers the potential for widespread CNS transduction with a
minimally invasive injection.

An added advantage is that very little serum IgG crosses

into the CSF, making intrathecal vector delivery insensitive to the presence of preexisting antibodies against the AAV capsid, potentially extending this approach to
individuals who would not be candidates for systemic vector delivery (Haurigot et al.
2013).
The transduction pattern achieved with IT AAV suggests some clear clinical
applications. The efficient transduction of spinal cord motor neurons shows strong
potential for the treatment of lower motor neuron disease. The transduction of a fraction
of cells throughout the cerebrum may not be sufficient for many diseases in which a
defective gene is essential for function of every cell. However, for many of the lysosomal
storage diseases, in which some of the enzyme produced can be secreted and taken up
by neighboring cells, even a relatively small number of cells spread throughout the brain
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could lead to widespread correction (Sando and Neufeld 1977). Efficacy has already
been demonstrated in animal models of diseases such as MPS IIIa, and MPS I, and
other diseases that exhibit cross correction may also be good targets for intrathecal AAV
delivery (Haurigot et al. 2013, Hinderer, Bell, et al. 2014a). For lower motor neurons, an
extremely promising target is SMA.

Intrathecal AAV9 delivery has been shown to

efficiently rescue the neuromuscular phenotype in mice, and parallel studies in
nonhuman primates demonstrate that levels of transduction required for efficacy can
readily be achieved in large animals at moderate vector doses (Meyer et al. 2014,
Passini et al. 2014).

Intrathecal AAV9 expressing an shRNA against superoxide

dismutase 1 (SOD1) has also shown promise in animal models of dominantly inherited
amyotrophic lateral sclerosis, effectively reducing levels of the toxic protein in lower
motor neurons (Foust et al. 2013). However, ALS also affects upper motor neurons
residing in the cerebral cortex, and the impact of the vector on SOD1 expression in
these cells has not been demonstrated.
Expanding on the success of intrathecal AAV delivery and bringing this approach
to new disease targets will require that several issues are addressed. One is a problem
of animal models. Preclinical studies should ideally be carried out in a model that not
only reflects that pathophysiology of the disease, but also is amenable to the clinical
route of administration and consequently exhibits the vector biodistribution expected
patients. Knockout mouse models may be problematic for these studies, since some
routes of intrathecal administration are technically challenging to replicate in these
animals.

Intraventricular delivery is readily carried out in mice, although the vector

distribution resulting from intraventricular delivery in the small mouse CNS clearly differs
from that in larger animals (Haurigot et al. 2013). For some diseases the availability of
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large animal models will facilitate this process. We used canine and feline models to
develop IT gene therapy for MPS I. Large animal models have been identified for many
other lysososmal storage diseases, such as MPS VII, mannosidosis, GM1 and GM2
gangliosidoses, and an induced model was developed in pigs to evaluate IT gene
transfer for SMA (Duque et al. 2015, Haskins 2009). For many other diseases, however,
no large animal model will be available. Extrapolating biodistribution data from large
animals may help to inform efficacy assessments in mouse models.

For example,

studies using SMA mice evaluated the extent of motor neuron transduction necessary to
rescue the disease phenotype, then used reporter gene studies in nonhuman primates
to identify a dose capable of similar transduction levels (Meyer et al. 2014, Passini et al.
2014).

More creative approaches like this may be essential to developing IT gene

therapy for diseases for which only mouse models are available.
A second important issue that will need to be considered is the potential for
systemic distribution of a vector after IT delivery. Studies in dogs, mice, nonhuman
primates, and cats have shown peripheral transduction after IT delivery (Hinderer, Bell,
et al. 2014a, Hinderer, Bell, Vite, et al. 2014, Haurigot et al. 2013).

This finding has

revealed further limitations of the prevailing view of CSF circulation—in the past it was
thought that CSF was resorbed entirely through arachnoid granulations of the meninges,
which is inconsistent with the observation of efficient and rapid escape of viral particles
from CSF to blood.

This finding is, however, consistent with the more recent

identification of perivascular channels and CNS lymphatics that allow for drainage of
particles from CSF to the periphery (Iliff et al. 2012, Iliff et al. 2013). The implications of
peripheral distribution will vary depending on disease—in the lysosomal storage
diseases, systemic distribution and liver transduction may actually be beneficial, as
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these enzymes are ubiquitously expressed and can treat somatic as well as CNS
disease. However, for many other diseases hepatic targeting may be detrimental and
additional measures such as tissue specific promoters may be needed to achieve
adequate safety.
Another important issue for IT AAV delivery is that of dose scaling between
animal models and patients. For systemic applications dosing has typically been based
on body weight. For intrathecal delivery, the vector dose should presumably be based
on the targeted compartment, since the primary activity and toxicity of the vector would
be expected to be based on the concentration of vector in CSF. CSF volume does not
exhibit a static relationship with body weight across species or animals of different ages,
so it will be important to scale doses according to the actual size of CNS.

Rather than

basing doses on CSF volume, our approach has been to scale doses based on brain
mass, since much more detailed data are available for humans and animals of different
ages, and because brain size appears to have a linear relationship with CSF volume
across species. Since there is systemic distribution of vector after IT delivery, it will be
important to also consider the dose relative to body weight when comparing doses found
to be safe in preclinical studies with those used in first in human trials to avoid potential
systemic toxicity. This could be especially important in infants, whose brain to body
mass ratio is greater than that of animal species commonly used for toxicology studies.
To expand IT AAV delivery to new targets it will be important to better elucidate
the transduction patterns in the CNS. Motor neurons are clearly efficiently targeted in all
species, but the other cell types transduced have varied between studies. In nonhuman
primates we have observed predominately neuron-restricted expression, particularly the
pyramidal cortical neurons and purkinje cells in cerebellum (Hinderer, Bell, Vite, et al.
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2014). Others have reported more extensive glial transduction, including astrocytes and
oligodendrocytes (Samaranch, Salegio, et al. 2013, Bucher et al. 2014b). For some
disorders in which the transgene product can be secreted, targeting any cells in the CNS
could potentially be beneficial. For other disorders, particular cell types and even very
specific functional subsets of neurons may need to be transduced for efficacy, and
transduction of other cell types may be toxic. This may necessitate careful capsid and
promoter selection to achieve the required degree of selectivity.
Progressing IT gene transfer will also require a broader understanding of the
factors leading to immune responses in CNS and the consequences of immunity. IT
delivery appears to circumvent the T cell-mediated immune response to transgene
products that has been observed with intraparenchymal delivery; however there has
been one report of potential immunological toxicity after intrathecal AAV9 delivery
expressing GFP in a nonhuman primate, indicating the need for careful monitoring and
more detailed studies (Samaranch, San Sebastian, et al. 2013).

The potential for

antibody responses to secreted transgenes in the CNS will also be important. In MPS I
dogs there was a high rate of antibody induction to the transgene product, which while
not associated with toxicity, did reduce the efficacy of cross-correction. The clinical
experience with intrathecal delivery of the enzyme indicates that antibody induction
against the protein in CSF is not likely to occur in humans, but this provides an important
example of a potential challenge for IT gene therapy with secreted transgene products
(Vera et al. 2013). We have demonstrated that such responses can be prevented in
MPS I dogs and nonhuman primates through exposure to the enzyme in the first week of
life, which could be a viable approach for diseases in which newborn screening is
commonly employed. This method can also be useful for preclinical studies of vectors
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expressing human proteins as a means of preventing antibody responses to the nonspecies-specific transgene which would otherwise preclude evaluation of efficacy in
animal models.
Another critical issue for IT AAV delivery will be the route of administration.
There are many potential routes for CSF access; lumbar puncture is the most common,
but cannulation of the lateral ventricle is also possible, and CSF can be accessed at the
cervical level by lateral C1-2 puncture or suboccipital puncture. Our group and others
have found that lumbar puncture results in very inefficient delivery of vector to the brain,
whereas delivery into the cisterna magna by suboccipital puncture results in efficient
transduction in both brain and spinal cord (Hinderer, Bell, Vite, et al. 2014). Suboccipital
puncture is not commonly used clinically due to the greater risks that were associated
with targeting near the brainstem and surrounding vessels in the pre-imaging era,
although today the procedure can be readily performed with image guidance (Saunders
and Riordan 1929, Pomerantz, Buchbinder, and Hirsh 2005).

CSF access is also

routinely achieved at approximately the same location by lateral puncture of the dorsal
subarachnoid space between the first and second vertebrae. We have found that this
approach is not feasible in MPS I patients due to abnormal thickening of the cervical
meninges, although C1-2 puncture may be a reasonable option for many other
applications. Future preclinical studies would be needed to verify similar distribution after
C1-2 puncture relative to suboccipital puncture.

Finally intraventricular delivery is a

possibility, and has been shown to result in biodistribution similar to intracisternal
delivery in dogs (Haurigot et al. 2013).

However, ventricular delivery has the

disadvantage of the requirement for a neurosurgical procedure. Also, the penetration of
the brain parenchyma raises the possibility for the same type of localized inflammatory
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response and induction of immunity against the transgene product that has been
observed following intraparenchymal vector delivery.
IT AAV delivery represents a critical advance in our approach to the treatment of
inherited neurologic disease.

Gene therapy targeting the brain has slowly become

possible through the advent of AAV vectors, followed by the discovery of more efficient
serotypes for CNS gene transfer. The development of IT delivery represents a critical
next step in this process, providing for the first time a minimally invasive method to
deliver the vector to large portions of the brain and spinal cord. This will not be the final
solution for CNS gene therapy—there are still many diseases for which more extensive
transduction, precise regulation of transgene expression, or specific cell targeting will be
necessary for successful treatment.

However, IT AAV delivery has unlocked the

possibility of gene therapy for many previously elusive targets, and could pave way for
the first clinical successes for neurological disorders.
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